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ABSTRACT

Research in the pharmaceutical field involves investigation of a new drug, delivery route,
a delivery system, a technology to design the delivery system, or a combination thereof.
Scientists have explored several delivery routes such as oral, pulmonary, nasal, injection/implant,
transdermal/dermal, transmucosal etc. for their potential to transport a variety of small and large
drug molecules. In the present research work, oral route, a widely accepted route of
administration, for the delivery of products with a major market share, has been considered for
the delivery of poorly soluble actives. The use of appropriate carrier matrices (polymers) and
excipients help in incorporating these drugs and developing a dosage form/drug delivery system
with desired properties. The oral delivery systems are most popular, convenient for
administration, and mainly include conventional solid dosage forms such as pellets, tablets, and/
or milled material filled in capsules. Since most of the actives studied under current research
have low aqueous solubility, it was necessary to utilize a novel technology such as hot melt
extrusion (HME) in combination with hydrophilic polymers to obtain tailored drug release.
Over recent years HME technology has found widespread application as a viable drug
delivery option in the drug development process. Some of the HME applications include taste
masking, solid-state stability enhancement, solubility enhancement etc. Solubility enhancement
in the HME process occurs through the dispersion of a poorly soluble drug in a polymeric carrier
matrix essentially forming a solid dispersion. While this technology can help in producing
amorphous or crystalline solid dispersions depending upon several factors, solubility
ii

enhancement applications are centered on generating amorphous dispersions, primarily because
of the free energy benefits they offer. Amorphous solid dispersions result when melt extruded
drug-polymer is cooled at a rate that does not allow the drug to recrystallize, or processed at
temperatures where drug melts but remains immiscible with the carrier. Such processing results
in kinetic entrapment of the drug in its amorphous state. These dispersions also provide
maximum specific surface area and higher saturation solubility, which ultimately increase drug
solubility. Although these types of systems exhibit increased rate of dissolution due to high
thermodynamic activity, they have a potential to revert to the more stable crystalline form.
Thorough understanding of the physicochemical properties of amorphous solid dispersions and
their corresponding in vivo behavior is required for the realization of their true potential in the
pharmaceutical industry.
In the research projects outlined in this dissertation, the focus has been to characterize the
different hydrophilic polymeric extrudates produced utilizing HME technology, and emphasize
their pharmaceutical applications. HME, in conjunction with suitable polymers, has been
demonstrated as a viable approach to develop a novel pellet dosage form with potential abuse
deterrent properties. In addition, its application for solubility enhancement aims at generating
amorphous solid dispersions utilizing novel hydrophilic polymers, followed by the in-depth
characterization of the produced melt extrudates. Moreover, the effect of various formulation
variables and process parameters has also been investigated. This underlying research also
facilitates the development of a wide-ranging stable solid oral dosage forms with modulated drug
release.
iii

The key objectives of the chapters in the dissertation are: (1) To develop an abusedeterrent (AD) platform technology in the formulation development utilizing HME technique;
(2) To investigate the effect of process variables and formulation factors on characteristics of hot
melt extrudates containing hydrophilic vinylpyrrolidone/vinyl acetate copolymer (Kollidon® VA
64); (3) To investigate the feasibility of producing stable drug-loaded Soluplus® extrudates
utilizing HME technology, and to study the influence of formulation and processing parameters
such as drug-load and heating duration, respectively, on the drug-polymer miscibility as well as
the release from melt extrudates; (4) To explore the feasibility of producing soluble Soluplus®Curcumin extrudates utilizing HME technology, including the drug-polymer miscibility studies,
and the influence of surfactants on dissolution rate of this poorly water-soluble model drug.
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CHAPTER - 1
Hot Melt Extrusion: A Promising Technique to Produce a Novel Abuse-Deterrent/TamperResistant Formulation
1.1.Introduction
In recent years, prescription drug abuse has been identified as source of rapidly growing
concern in the United States. Of all the available drugs, Opioids, CNS depressants and stimulants
are the three most established drug classes that are abused, next to marijuana (1). Pain, being a
potentially debilitating symptom associated with a variety of chronic medical conditions, has
necessitated the application of numerous opioids, which have a high potential for abuse. The
number of prescriptions for these drugs has also increased considerably over the past two
decades (2). Moreover, as per one of the national surveys, more focus on the non-medical use of
these opioids has been noticed in all of the different age groups, teenagers being a major
constituent amongst those abusers (3, 4). In addition, the number of emergency visits as well as
the death rates due to overdose of these medications has increased dramatically over the past few
years (5). These drugs, being reasonably accessible to the population, have been largely misused
or abused via physical or chemical manipulation in order to obtain high drug concentration in the
body to produce euphoric effects, or a significant “high”.
The majority of the opioids/ controlled substances that have shown potential for abuse are
available in the form of immediate release (IR) and extended release (ER) tablets and capsule
dosage forms, trans-dermal patches, trans-mucosal lozenges etc. The consumption of more
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number of IR units via oral route results in higher concentrations of the drug in the systemic
circulation, producing the desired “high” (6). In addition, there has been a marked interest in
manipulating the ER dosage forms due to the large dose of the drug per unit dosage form (7).
Apart from the oral route, alternative delivery routes have been explored by the abusers to
achieve a similar psychological feel in a short period or with a limited amount of material in
hand (8). Since these conventional formulations are not hard enough to resist crushing, the
obtained powder-like fine material is easily snorted via nasal route. In the same scenario, if the
active is highly soluble in the aqueous medium, it could be extracted in a small volume and
injected directly into the blood stream to get an instantaneous “high.” Some of the other drugs
with higher vapor pressures are abused or misused by smoking or volatilization (9). An
epidemiologic study conducted on the subjects who were addicted to Oxycontin (Oxycodone
HCl), have reported that majority of the users have started taking the drugs orally, but over the
time have advanced to administering the API through different routes: 62% reported snorting,
26% through injecting, and only 14% by oral route (10).
Due to this alarming issue, the recent interest of several pharmaceutical industries has
been shifted towards developing a platform technology, which either prevents or minimizes the
abuse of, or tampering with, the prescription opioids. Currently, there are surprisingly few
formulations that are either under development or commercially available in the United States
that demonstrate such properties (11). Some of the marketed products that are currently approved
by United States Food and Drug Administration (FDA) are Oxycontin ® OP ER tablets, Oxecta
IR tablets, Suboxone sublingual tablets, Nucynta ER tablets, and Opana ER tablets. These
emerging opioid containing formulations were produced by novel approaches such as
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incorporation of gelling agents, nasal irritants, antagonists etc., in the formulations. Thus, they
are not only designed to discourage the abusers by reducing the risk of misuse and/or abuse, but
are also dually beneficial to physicians in meeting their goals of maximizing pain relief in
afflicted populations. However, none of these formulations can guarantee an absolute abuse
deterrence/tamper proof. In addition, the majority of these formulations have been produced via
conventional methodologies involving several processing steps such as wet/dry granulation,
blending, compression, curing, coating, etc., which adds longer time and higher cost to the
development process.
Although research in this particular area has gained enormous attention due to the
pressure from the law makers and the FDA, there is not much literature published/available,
especially on the TR formulations developed utilizing novel hot melt extrusion (HME)
technology. In a recent study by Bartholomaeus et al. the authors produced an ER opioid
formulation with crush-resistant features using a combination of a planetary-gear extruder and a
tablet press on a laboratory scale, which involved few processing steps (12). However, their
primary objective was to stabilize the formulation and be bioequivalent to the marketed ER
formulation. In addition, the rationale for their formulation selection does not involve DOE and
necessitates further discussion.
The objective of this current research is two-fold. Firstly, utilizing a DOE approach and
employing HME processing in identifying and producing an optimal formulation. Secondly, to
produce TR formulations that is more resistant to crushing/grinding/milling (to avoid
insufflation), and to minimize the drug extraction (to avoid abuse via injection). HME is a novel
and viable technique that has been effectively utilized in the pharmaceutical industry to improve
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the bioavailability of the actives, especially those having low aqueous solubility, by formation of
molecular dispersions (13-15). This technique is also time-efficient and cost-effective, due to the
involvement of fewer processing steps, and utilization of limited excipients. In this study, we
have made a sincere attempt to demonstrate the capability of single-step HME technology in
producing a TR formulation utilizing appropriate commonly used excipients (16, 17). It should
be noted that the terms ‘TR’ and ‘AD’ may be used interchangeably throughout this paper.
1.2.Materials and Methods
1.2.1. Materials
Lidocaine HCl (LID) and Vitamin E Succinate (VES) were purchased from spectrum chemicals
(Decatur, AL, USA). PolyOx™ WSR 301 (PEO-301), and PolyOx™ N80 (PEO-N80) were
kindly gifted from Colorcon (West point, PA). Benecel™ K4M (HPMC K4M), and Benecel™
K15M (HPMC K15M) were kindly gifted from Ashland Inc. (Wilmington, DE). Eudragit®
RSPO (EUD) and Carbopol 71G (CBP) were kindly gifted by Evonik (Piscataway, NJ), and
Lubrizol (Cleveland, Ohio), respectively. Dibasic potassium phosphate and tribasic sodium
phosphate were purchased from sigma-Aldrich (St. Louis, MO). High performance liquid
chromatography (HPLC) grade water was freshly prepared in the laboratory by Nanopure
systems (Barnstead, Dubuque, IA, USA). All solvents utilized in the study were of analytical
grade and obtained from Fisher Scientific (Fair Lawn, NJ, USA).
1.2.2. Analytical Method
An in-house reverse phase high performance liquid chromatography (HPLC) based analytical
method was developed for the determination/quantification of LID. This method was validated
according to ICH and FDA guidelines for chromatographic methods. An HPLC equipped with a
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UV detector, Waters Symmetry shield 5μ C18 column (250×4.6 mm), and an isocratic mode of
elution with the mobile phase consisting of 20mM ammonium acetate with 30mM TFA,
acetonitrile, and methanol (70:10:20) at a flow rate of 1.2 mL/min were employed to quantify the
drug at a wavelength (λmax) of 254 nm. The acquired data was processed using Empower 2
build 2154 software (Waters Inc., Mount Holly, NJ, USA).
1.2.3. Preparation of Physical Mixtures/ Blends
Prior to extrusion, the required materials were sieved through a USP # 30 (600µM) mesh,
accurately weighed, and transferred to a twin-shell V-blender (The Patterson-Kelly co., Inc. East
Stroudsburg, PA). The materials were then mixed at 25rpm for 10 minutes in the V-blender to
obtain a homogeneous blend.
1.2.4. Preparation of Hot Melt Extrudates
1.2.4.1.HME: Initial Screening
In order to identify a suitable carrier matrix to produce an AD/TR formulation, different
polymers such as HPMC K4M, HPMC K15M, PEO-301, and EUD were evaluated for
extrudability at barrel temperatures ranging from 110°C-180°C and a screw speed of 50 rpm in a
twin-screw compounder (MiniLab II HAAKE Rheomex CTW5, ThermoFisher Scientific). The
polymeric matrices selected from those tested, (i.e. PEO-301 & EUD, and their blends mixed in
ratios of 1:1, 2:1, and 1:2 PEO-301 and EUD respectively) were extruded with LID at barrel
temperatures ranging from 110˚C-130˚C and a screw speed of 50 rpm utilizing a lab scale twinscrew Hot Melt extruder (Prism 16mm EuroLab, Thermo Fisher Scientific) with 3mm diameter
circular die. All of the extrudates contained 10% w/w VES as a processing aid and 20% w/w
LID. The obtained extrudates were cut to a length of 3mm using a bench-top pelletizer (Thermo
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Fisher Scientific) and stored appropriately until further testing.
1.2.4.2.HME: Box-Behnken DOE
Based on the results from the initial screening, PEO-301 was chosen as the carrier matrix, while
HPMC K15M and CBP were employed as gelling agents; each of these were designated as a
formulation factor. Box-Behnken design (Table 1-1) was used to determine the effects of the
three formulation factors, each at three levels, on TR characteristics of the melt-extruded pellets.
A response surface methodology was utilized to identify the optimized formulation. A total of 14
formulations, including two center points, generated by the design were extruded at temperatures
ranging from 110˚C-130˚C and a screw speed of 50 rpm using a twin-screw hot melt extruder
(Prism 16mm Eurolab ThermoFisher Scientific). The final extrudates were then cut to 3mm in
length using a bench-top pelletizer (ThermoFisher Scientific) and stored until further testing.
Table 1-1: Box-Behnken Design for the Three Formulation Factors (PEO-301; HPMC
K15M; and CBP) Under Study
Std Order

Run Order

Pt Type

Blocks

PEO-301

2
13
5
8
14
10
6
12
1
11
9
3
7
4

1
2
3
4
5
6
7
8
9
10
11
12
13
14

2
0
2
2
0
2
2
2
2
2
2
2
2
2

1
1
1
1
1
1
1
1
1
1
1
1
1
1

40
30
20
40
30
30
40
30
20
30
30
20
20
40
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HPMC
K15M
10
15
15
15
15
20
15
20
10
10
10
20
15
20

CBP
6
6
2
10
6
2
2
10
6
10
2
6
10
6

The experimental design and data analysis were conducted using Minitab® 15.0. The current
response surface methodology DOE was analyzed using multiple regression statistics. A full
quadratic model was fitted to the collected responses, and ‘P’ values for each of the factors were
used to determine their significance. Highest order, most insignificant terms were sequentially
removed until the significant factors were identified. Residual analysis was performed on the
final reduced model, and the developed model was validated by executing and analyzing a
confirmation run.
1.2.5. Weight Variation
Twenty pellets from a 100g batch were randomly selected from each of the DOE formulations
and weighed using a Sartorius lab scale digital balance. The values were recorded, and the mean
± standard deviation (SD) was calculated.
1.2.6. Hardness and Friability Testing
The diametric compression strength testing was performed on ten randomly picked pellets per
formulation using the Varian tester, and the hardness values were recorded.
The friability testing was performed on a sample of approximately 6.6g of extruded pellets
utilizing a Varian friabilator. Pre-weighed pellets were placed in a friabilator and rotated at a
speed of 25rpm for 4min. The pellets were then de-dusted, reweighed, and percentage weight
loss (friability) was calculated for all of the DOE formulations.
1.2.7. Fine particle reduction
The obtained pellets equivalent to 200mg of weight from each of these formulations were
evaluated for particle size reduction. The pellets were initially subjected to a low-shear grinding
in a mortar and pestle for about 5min, followed by milling using a coffee grinder for an
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additional 5min. The obtained particles (n=3) were passed through a USP # 100 (150 µm) mesh,
and the fraction retained on the sieve was recorded.
1.2.8. Drug Extraction in Water
200mg of extruded pellets (equivalent to 40mg of LID) were added to 5ml of de-ionized water in
a 20mL scintillation vial. Each of these formulations was vortexed for 2 minutes and kept aside
for 30 minutes. At the end point, the samples were further mixed, and an aliquot of 1mL was
collected, further diluted with methanol, filtered using 0.2 µm, 13mm PTFE membrane filters
(Whatman, Piscataway, NJ). These solutions were analyzed using an HPLC at a wavelength of
254 nm. The test was performed in triplicate and the mean ± SD were recorded. Additionally,
these resultant solutions/dispersions have been qualitatively assessed for an increase in the
viscosity or by visual observation for gel formation.
1.2.9. Drug Extraction in Alcohol
The extruded pellets (200mg) with a dose containing approximately 40mg drug were taken and
dispersed in 60mL of 50% v/v absolute alcohol (simulating one large shot of whiskey). Each of
these formulations was vortexed for 2 minutes and kept aside for 30 minutes. At the end point,
the samples were further mixed, and an aliquot of 1mL was collected, diluted with methanol,
filtered using a 0.2 µm, 13mm PTFE membrane filters (Whatman, Piscataway, NJ), and analyzed
utilizing an HPLC at a wavelength of 254 nm. The test was performed in triplicate and the mean
± SD were recorded.
1.2.10. Drug Release Studies
The in vitro dissolution studies were carried out on the extruded pellets containing PEO, EUD,
and their blends as polymeric matrices with approximately 40mg of LID. The pellets are
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weighed accurately and filled in size#1 gelatin capsules. Dissolution testing (USP XXXI,
Apparatus II) was performed utilizing a Hanson SR8-plus™ dissolution test station (Hanson
Research Corporation, Chatsworth, CA) operated at 100-rpm paddle speed. The dissolution
medium consisted of 750mL of 0.1N hydrochloric acid (pH 1.2), preheated to 37°C. After 2hrs,
250mL of 0.2M tribasic sodium phosphate was added to the existing medium in the dissolution
vessel and the pH of the entire medium in the dissolution vessel was adjusted to pH 6.8 by
adding either 2N HCl or NaOH. An aliquot of 1.5mL was collected at pre-determined time
intervals, filtered, and analyzed using an HPLC at a λmax of 254nm. Drug concentrations were
calculated from a standard calibration plot and expressed as cumulative percentage drug
dissolved. The release studies were also performed in triplicate and the mean values were
compared.
1.3. Results
1.3.1. Analytical Method
The validation of the HPLC method employed in this study was carried out as per the ICH and
FDA guidelines for chromatographic methods. The linear calibration range for the detection of
LID was found to be 5-200 μg/mL, with a coefficient of determination (R2) of 0.999. The limit of
detection and quantitation for the drug were 0.3 and 1.0 µg respectively, and the retention time
for LID was 8.9 minutes. The percentage relative standard deviation (RSD) within replicates
(n=3) was less than 2.0%, which demonstrates the reproducibility of the method. Precision was
tested by injecting a single drug concentration (20μg/mL) 10 times, and the peak area was
recorded and evaluated. A precision of less than 1.0% of RSD was observed.
1.3.2. Weight Variation, Hardness and Friability Testing
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For all of the formulations, the weight and length of the pellets were within 28mg±10% and
3mm±5%, respectively. The hardness of the extruded pellets increased as the concentration of
PEO-301 in the extruded pellets increased. This seemed especially true when the concentration
of PEO-301 exceeded 50% of the total polymer weight. Moreover, the pellets made of pure
PEO-301 could not be broken, but could only be deformed by the apparatus. A maximum
hardness of 35kP was displayed on the instrument. This indicates a plastic behavior as a result of
thermoplastic nature of the PEO-301 (Figure 1-1). Friability values were less than 0.1% in all of
the DOE batches produced.

Note: The extrudates prepared from PEO-301 (pure PolyOx™ WSR 301) could only be
deformed, but not broken during the hardness evaluation.
Figure 1-1: Hardness Evaluation of the Preliminary Melt-Extruded Pellet Formulations
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1.3.3. Fine particle reduction
All of the particles obtained from grinding the extruded pellets in a mortar and pestle, followed
by milling in a coffee grinder, were completely retained on the USP # 100 mesh screen (>150µ).
1.3.4. Drug Extraction in Water
The intact pellet formulation with pure PEO-301 had 27.4% of the drug extracted in water
(approximately 11mg out of 40mg of LID) over 30 minutes, whereas all of the other
formulations have shown higher drug extraction (>50%) over the same period (data not
presented). The formulation with pure PEO-301 visually demonstrated a superior gel formation
when compared to the other formulations.
1.3.5. Drug Extraction in Alcohol
The observed drug extraction in alcohol (ethanol) was only 21.3% from the intact pellets
containing pure/unblended PEO-301 in comparison to those made with pure EUD, which was
approximately 50% of LID loading. The percentages of drug extracted in alcohol from all of the
other intact pellet formulations were found to be between that of the pure polymer compositions.
In addition, milled pellets exhibited significantly higher drug extraction compared to the intact
pellets as depicted in Figure 1-2.
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The pellets made of PEO-301 could not be milled into fine powder. Hence, this sample was not
tested for drug extraction in alcohol from the Hot Melt extruded pellets.
Figure 1-2:

Drug Extraction in Alcohol from the Preliminary Melt-Extruded Pellet

Formulations
1.3.6. Drug Release Studies
All of the extruded formulations, irrespective of their polymeric compositions (varying PEO:
EUD ratios), have demonstrated similarity factor values (f2) of greater than 50. The pellets
composed of PEO-301 alone with 20% LID served as the reference (Figure 1-3).
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Figure 1-3: Drug Release from the Preliminary Melt-Extruded Pellet Formulations
1.4. Discussion
Due to controlled and restricted access to opioids, an active with high water and alcohol
solubility (LID) was chosen as a model drug in the current study. Different carrier matrices such
as HPMC K4M, HPMC K15M, PEO-301, and EUD were initially screened to identify suitable
carriers that exhibit AD/TR properties. When attempting to extrude neat polymers at 90% w/w
polymer level, formulations containing HPMC could not be extruded even at temperatures as
high as 180°C. Irrespective of its molecular weight, HPMC could not be plasticized under the
employed extrusion conditions, and consequently was not pursued further as a carrier matrix. On
the other hand, PEO-301 and EUD were easily extruded at a much lower temperature range of
13

125-140°C. The next level of screening involved studying the effects of chosen polymeric
carriers (PEO-301 and EUD) and their combinations at three different ratios to produce
formulations with AD/TR features. All of these five formulations could be extruded relatively
easily, and without incident. These formulations were subjected to hardness, crushing, extraction
and dissolution testing to choose the best carrier among those tested, that is, the one with the
most favorable AD/TR properties.
Snorting/insufflation is one of the most convenient and predominant modes of drug
abuse, where the tablet formulations are finely crushed and inhaled or “snorted” via nasal route
to get rapid onset of action. When inhaled intra-nasally, drugs could reach both the brain (bypassing the blood-brain barrier), and the systemic circulation (by-passing intestinal and hepatic
metabolism). Targeting the drugs to the brain would be the most effective approach to get an
instant “high” if the particles could get deposited in the olfactory region (required particle size
<5 µm), which facilitates the drug’s entrance into the cerebrospinal space (18). However, this
small particle size could also result in the drug deposition in the lower airways. Conventional
nasal formulations, on the other hand, maintain a particle size of 20-30 µm to facilitate their
permeation across the highly vascularized nasal mucosal epithelium (18). However, because of
the low volume availability in the nasal environment, the rate-limiting step for drug absorption
would be drug dissolution. Therefore, to produce a formulation with TR properties, it is required
to alter the formulation such that the particle size could not be minimized to an appreciable
extent. This results in a decreased surface area and ensures slower drug dissolution in the
available low volume nasal cavity. It has been demonstrated in this study that all of the pellet
formulations obtained from either pure EUD or its combination with PEO-301 could be broken,
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but not reduced into very fine particles as was attempted by the milling process in a coffee
grinder (Figure 1-4).

Figure 1-4: Visual Comparison of Different HME Pellet Formulations before and after
Particle Size Reduction
Another route of abuse that has gained considerable attention, and is highly favored
among abusers, is through extraction of the drug into aqueous solvent and injecting it directly
into the blood stream. To prevent this, a TR formulation should be able to gel sufficiently when
in contact with the aqueous media in order to minimize drug extraction. All of the extruded pellet
formulations, except the one containing pure EUD, exhibited a reasonable gelling tendency in
water. Moreover, the formulation extruded with pure PEO-301 has demonstrated increased
swelling and produced a superior viscous gel relative to the other formulations. Although the
high molecular weight PEO-301 does hydrate and subsequently forms an extraction preventative
gel layer, polymer hydration tends to occur somewhat more slowly than small molecule
dissolution. The coupling of these two events could have resulted in the drug’s escape prior to
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the gel formation event. On the other hand, EUD being a copolymer of ethyl acrylate and methyl
methacrylate, and having a low content of the methacrylic acid ester with a quaternary
ammonium group, it is less permeable and practically insoluble in water and might have
undergone erosion. Hence, as the EUD concentration in the formulation increased, the drug
extraction from the intact pellets might also have increased due to both high drug solubility
leading to diffusion through any formed channels, and lack of EUD gelling in the aqueous phase.
Apart from the aqueous media, extraction studies were also carried out in hydro-alcoholic
solutions. This increased drug extraction from EUD pellets was attributed to the higher solubility
of both the EUD polymer and drug in alcohol. Apart from testing the whole pellets, all of the
extrudates were subjected to milling and the milled portions were also exposed to alcohol for
LID extraction. As expected, due to an increase in surface area as a result of milling, all of these
formulations under investigation have shown much greater drug release in alcohol (60-90%)
when compared to the intact pellets (21-50%). The percent drug extracted between intact and
milled pellets for all of the tested formulations was statistically significantly different (p<0.05).
However, the drug extraction from the milled PEO-301 pellets could not be performed as the
pure PEO compacts were very plastic in nature and, as previously mentioned, very difficult to
crush.
The obtained dissolution data was fitted to different release models, and the drug release
mechanism from all of these formulations was established using the Krosmeyer-Peppas model.
The high coefficients of determination (R2) values were observed when plotted as per the
Higuchi equation, which indicates that, the regression line fits the data well. Additionally, the
calculated ‘n’ values for all of these five preliminary formulations were in the range of 0.28-0.37,
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which indicates that the drug’s release is mainly by fickian diffusion.
PEO-301, being a hydrophilic polymer, demonstrates rapid hydration and swelling of the
polymer when in contact with the aqueous media resulting in the formation of a uniform gel
layer on the surface of the matrix. Since the model drug under investigation is highly watersoluble, it quickly gets dissolved in the media and diffuses out through the channels formed due
to polymer swelling (19). However, the molecular weight of the polymer under discussion, PEO301, is relatively high (4 million), resulting in a slower gel erosion and a prolonged drug release
behavior, which translates to reduced extractability. On the other hand, although the EUD
matrices hydrate to a lesser extent, the drug release follows a similar mechanism of diffusion.
This could be attributed to the high aqueous solubility of the LID that diffuses through the
channels formed due to EUD erosion, or dissolution of other soluble formulation components.
The study results were in accordance with the previously reported data in the literature (20).
Based on the preliminary results obtained from the above studies, it has been concluded
that the pure PEO-301 extrudates exhibited the most suitable properties as an AD/TR carrier
matrix when processed by HME. However, these pellets need further improvement to minimize
the drug’s extraction in aqueous media, thereby preventing intravenous drug abuse. In order to
improve the formulation further, excipients such as CBP and HPMC K15M were employed as
gelling agents, and Vitamin E Succinate (VES) was used a processing aid in all of the
formulations. Both of these polymers, each at three different levels, were studied as gelling
agents to increase the viscosity of the formulation when in contact with water.
CBP was studied in a broad range of concentrations (2-10% w/w). In general, if the
concentration of CBP in the formulation is beyond 3%, it could potentially exhibit pH dependent
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drug release, which is not desirable. However, the grade of CBP chosen is a granular form, and
requires a high concentration (~10% w/w or higher) in the formulation to demonstrate gelling
and pH dependency. For CBP to act as a gelling agent, an alkaline environment is required to
ionize the polymeric chains and induce swelling for gel formation. Therefore, K2HPO4 was
added as a buffering agent in the formulation. Furthermore, researchers have utilized HPMC up
to 30% w/w in controlled release tablet formulations to provide sufficient gelling. However,
when used at high levels, there is a potential for the development of a brittle formulation that
could be crushed easily and compromise the insufflation inhibiting feature. When a minimal
amount of HPMC is used, there is a possibility of insufficient gel formation in water leading to
enhance drug extraction. As our primary intent was to improve the extraction in water (learning
from the preliminary experiments), 10-20% w/w range was assumed to be reasonable to study.
With several ingredients present in the formulation, a DOE was performed to optimize the levels
of PEO-301, HPMC K15M and CBP to produce a formulation with better TR/AD features
keeping all of the other components unchanged except for PEO-N80, which was used as filler.
The base formulation composition utilized for DOE and its excipient functionality is presented in
Table 1-2.
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Table 1-2: Composition and Functionality of Hot Melt Extruded Base Pellet Formulation
Utilized in Design of Experiments

Formulation Components

Concentration (% w/w)

Functionality

Lidocaine HCl (LID)

20

Active

PEO-301

20 – 40

Gelling Polymeric Matrix

HPMC K15M

10 – 20

Gelling Polymeric Matrix

Carbopol 71G (CBP)

2 – 10

Gelling Agent

Vitamin E Succinate

10

Process Aid

K2HPO4

1

Base/Gel Promoter

PEO-N80

3 – 33

Polymeric Filler

All of the extruded formulations produced under DOE were evaluated for various TR
tests and the obtained results were considered responses for optimization. The TR tests
performed were: (a) hardness testing using a Varian hardness tester; (b) fine particle reduction
using a mortar & pestle and a coffee grinder, followed by passing the milled extrudates through a
100 mesh screen; (c) extraction of the active pharmaceutical ingredient (API) in water; and (d)
extraction of the API in 60mL of 50% v/v absolute ethanol.
A total of 14 formulations produced under the Box-Behnken design, including two center
points, were easily extruded at the employed conditions. This design is a more efficient DOE
compared to a full factorial or a central composite design with an equal number of factors. The
Box-Behnken design uses edge midpoints; the design is run at a condition halfway between two
crners rather than at a corner. Moreover, this design does not use axial points. Hence, all of the
design runs will be within the initial design space. This feature is useful when it is necessary to
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ensure that all design runs are in defined or “safe” operating space.
Hardness testing revealed that all of the produced formulations were plastic in nature and
deformed. A maximum hardness value of 35kP was recorded on the instrument. None of the
pellets subjected to testing could be broken. LID pellet formulations demonstrated good postprocessing drug content (approximately 99.0% and a relative standard deviation of 2.0%). In
addition, a low-shear pulverization using mortar & pestle, followed by milling in a coffee grinder
generated particles with reduced size in all of the DOE formulations. However, none of these
formulations passed through mesh # 100 when subjected to sieve analysis, and the particle size
of all of the milled portions were larger than 150µ, which is indicative of the formulations’
resistance to snorting/insufflation. As mentioned earlier, the larger the particle size, the smaller
the surface area, which could lead to a relatively slower dissolution and lower absorption across
the nasal environment.
All of the formulations exhibited an appreciable gelling tendency in water with only 812% of drug being extracted. Good gelling behavior in water is attributed to the water uptake
potential of the employed hydrophilic polymers present in the formulation and their ionizable
groups, due to the micro-environmental pH, resulting in an increase in the viscosity of the
aqueous medium. Studies in the literature have reported that HPMC in combination with CBP
demonstrated a synergistic effect with a stronger cross linking between the polymers leading to
the formation of a more firm gel structure because of the hydrogen bonding between the anionic
CBP and the HPMC. Additionally, interaction between non-ionic polymers has also been well
established in the literature. Some reports have mentioned that PEO in combination with HPMC
might be favorable when slower initial release is required from the matrices. Both PEO and
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HPMC, being hydrophilic and non-ionic polymers, are dually advantageous in that they can
facilitate a faster hydration of PEO-301, and could also result in the formation of a stronger gel
layer. This ultimately results in minimizing the drug diffusion from the swollen matrix while
simultaneously decreasing the erosion rate of the formed gel layer (21). Similar behavior was
also reported with HPMC in the presence of non-ionic hydrophilic polymer, hydroxylpropyl
cellulose (HPC).
When analyzing the percentage of the API extracted in water, the level of HPMC K15M
was the only factor that demonstrated a significant influence on the response (P<0.05). The R-Sq
(adjusted) value in the final reduced model indicated that the model explained 35% of the data
variability (Figure 1-5). In addition, the P value for ‘Lack-of-Fit’ was found to be 0.136
(P>0.05). Therefore, the null hypothesis was accepted i.e., the model developed is not different
from the proper fitting model. The reduced final model for this response can be provided as
follows:
Percentage API extracted in water = 8.085 + 0.172 (HPMC)..........Equation 1
The drug extraction in alcohol was another response that ranged from 17-45%, amongst
different formulations tested. Similar results were observed in a study conducted by Robert et al.
who studied the release of aspirin from HPMC matrix in hydro-alcoholic media (22). The
authors noticed an initial sudden burst release of the drug without causing any dose dumping,
which was attributed to the delayed hydration of HPMC in the alcoholic medium. Therefore, in
the present study both PEO and HPMC being insoluble in alcohol, high drug extraction in
alcohol was accounted for by the high solubility of LID as well as the delayed hydration of the
HPMC polymeric matrix in the presence of ethanol.
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Figure 1-5: Response Surface Regression after Model Reduction Obtained Using “Percent
API Extracted in Water” as a Response
‘Percentage API extracted in alcohol’ was also significantly influenced (P<0.05) by the
level of HPMC K15M employed in the formulation. When the obtained data was fitted to the
model, the R-Sq (adjusted) value in the final reduced model indicated that the model explained
34% of the data variability (Figure 1-6). In addition, the P value for ‘Lack-of-Fit’ was found to
be 0.377 (P>0.05). Hence, the null hypothesis was accepted i.e., the model developed is not
different from the proper fitting model. The reduced final model for this response can be
provided as follows:
Percentage API extracted in alcohol = 6.787 + 1.343 (HPMC)……….Equation 2
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Response Surface Regression: Alcohol Gelling versus HPMC
Final reduced Model: The analysis was done using uncoded units.
Estimated Regression Coefficients for Alcohol Gelling
Term
Coef SE Coef
T
P
Constant 6.787 7.5083 0.904 0.384
HPMC
1.343 0.4854 2.766 0.017
S = 6.86435
PRESS = 797.327
R-Sq = 38.94% R-Sq(pred) = 13.90% R-Sq(adj) = 33.85%
Analysis of Variance for Alcohol Gelling
Source
Regression
Linear
HPMC
Residual Error
Lack-of-Fit
Pure Error
Total

DF
1
1
1
12
1
11
13

Seq SS
360.60
360.60
360.60
565.43
40.52
524.91
926.03

Adj SS
360.60
360.60
360.60
565.43
40.52
524.91

Adj MS
360.60
360.60
360.60
47.12
40.52
47.72

F
P
7.65 0.017
7.65 0.017
7.65 0.017
0.85 0.377

Figure 1-6: Response Surface Regression after Model Reduction Obtained Using “Percent
API Extracted in Alcohol” as a Response
The standardized residual plots (Figures 1-7A and 1-7B) of the final reduced models for
the responses ‘percentage API extracted in water’ and ‘percentage API extracted in alcohol’
meet all of the basic assumptions of a good model fit. The figures indicate that the residuals are
normally distributed around approximately the mean of zero. Moreover, the residuals are
homoscedastic, also known as homogeneity of variance (residuals have constant variability and
are independent of fitted value), and do not show any trending (independent of observation
order). Response optimization plots (Figure 1-8A and 1-8B) indicated that lower extraction of
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API in water (9.8%) and alcohol (20.2%) could be achieved by using HPMC even at lower
concentrations (10% w/w level), when other factors are utilized at appropriate concentrations in
the formulation.
In order to validate the developed model, a confirmation batch utilizing PEO-301, HPMC
K15M, and CBP at 20%, 10% and 6% w/w, respectively, was produced and analyzed. The
predicted values obtained from the response optimizer were found to be similar to the observed
values of 9.4% and 19.5% respectively, for percentage API extracted in water, and percentage
API extracted in alcohol demonstrating the validity of the developed model. This final
formulation was studied for drug release along with other TR properties and found that almost
60-70% of the drug was released in 2-3hrs (data not presented). Although extended release
polymers such as PEO-301 and HPMC K15M were used as carrier matrices in the present study,
the observed faster dissolution rate in the initial hours could be attributed to the high water
solubility of the LID, as well as utilization of lower molecular weight PEO (PEO-N80) as a filler
in the formulation, which does not swell to a great extent and compromises the integrity of the
gel network relatively quickly as opposed to high molecular weight grade PEO polymers.
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Figure 1-7: Standardized Residual Plots on the Final Reduced Models for the Responses:
(A) Percent API Extracted in Water; (B) Percent API Extracted in Alcohol
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Figure 1-8: Response Optimization Plot for the HPMC (the only Significant Factor) on the
Responses: (A) Percent API Extracted in Water; (B) Percent API Extracted in Alcohol
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1.5. Conclusion
HME was demonstrated as a viable technique for the development of much needed
abuse-deterrent formulations. Moreover, high molecular weight grade polyethylene oxide was
shown to be utilized as a TR matrix, while HPMC K15M in combination with CBP significantly
improved the gelling characteristics in water and alcohol to prevent API extraction. The
optimized response models created for ‘percentage API extracted in water’ and ‘percentage API
extracted in alcohol’ also correlate well with the data generated, confirming its validity. Our
future studies will be focused to work with controlled substances as model drugs, and evaluate
newer excipients in conjunction with appropriate processing conditions to further improve the so
far developed formulation and fully characterize its dissolution and stability characteristics.
Although these formulations are termed as AD/TR dosage forms, these can never be completely
abuse-free as none can stop a determined person from abusing the drugs. Still, these developed
formulations would most likely serve the purpose as the abusers might definitely need to perform
an enormous amount of work, or exhibit uncharacteristic patience, to use them in an unintended
way. These formulations could also significantly reduce the deaths due to overdose, as well as
decrease the percentage of young children and patients with acute or chronic pain who might
convert into potential abusers.
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CHAPTER - 2
Characterization of Kollidon® VA 64 Hot Melt Extrudates: Influence of Formulation and
Process Parameters on Dissolution and Stability Characteristics

2.1.Introduction
In the recent years, several therapeutic compounds of complex nature were produced as a
result of high throughput screening and combinatorial chemistry. It has been estimated that more
than 40% of all of these produced new molecular entities suffer from solubility-limited
bioavailability. Oral delivery of such compounds presents one of the most frequent and
formidable challenges to formulation scientists. Myriad techniques such as spray drying (23),
solvent-evaporation (24), nanocrystal formation (25), complexation (26), and micronization of
API (27) etc., have been widely utilized in the industry to demonstrate the improved solubility
and/or dissolution rate of such BCS Class II drugs, thereby enhancing their bioavailability. In
addition, over the past couple of decades, HME technique has gained enormous interest amongst
researchers in improving the bioavailability of drug substances, especially those having low
water solubility, by formation of molecular dispersions (13, 14, 16, 17). Compared to other
techniques HME offers several advantages such as being solvent free and involving fewer
processing steps.
HME is the process of pumping raw materials with a rotating screw under elevated
temperature through a die into a product of uniform shape. These final extrudates obtained
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utilizing thermal energy may be in the form of films or rods that can be cut as tablets or pellets.
To date, several research papers have been published by scientists that focused on the
preparation of solid dispersions/solutions of numerous model drugs with low solubility such as
Clotrimazole (CTZ), Indomethacin and Nifedipine (NIF) etc. utilizing HME technique. Shibata
et al. produced solid solution of Indomethacin and crospovidone using twin-screw extruder, and
demonstrated that the parameters such as residence time, screw speed and heating temperature
play a significant role in the extrusion process (28). On the contrary, in a study by Verhoeven et
al., the effect of process parameters (screw design, feed rate and screw speed) on Metoprolol
tartarate and ethyl cellulose mini matrices were studied, and revealed that the process parameters
had no significant influence on drug quality as well as drug release, indicating robustness of
HME technique (29). In addition, the role of kneading paddle elements and operating conditions
of twin screw extruder on NIF and HPMCP extrudates were studied by Nakamichi et al. (30),
and concluded that all of these factors played an important role in obtaining ideal solid
dispersions. Most of these previous studies reveal that the influence of process parameters
primarily depends on multiple factors such as the API involved, the carrier matrix utilized, and
the processing conditions employed during the HME process.
In the current study, NIF (a dihydro pyridine calcium channel antagonist) was employed
as a model drug and Kollidon® VA 64 as the polymeric matrix. NIF is a light sensitive yellow
powder, practically insoluble in water, with a melting point of 172-174°C. It is a calcium channel
blocker used in the treatment of hypertension and angina. NIF is currently available as both
immediate and extended release tablet dosage forms given at a dose of 10-30 mg t.i.d. and 30-60
mg once daily, respectively, depending on the patient’s condition. The utilized polymer matrix,
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Kollidon® VA 64, is a vinyl pyrrolidone/vinyl acetate copolymer in 6:4 ratios. It is a hygroscopic
white powder, soluble both in water and alcohols and has a glass transition temperature around ~
106°C. It has several pharmaceutical applications such as a binder in tablets, a granulating agent
and a film former. The properties such as poor API oral-bioavailability of 45-56% due to
solubility limitations, and the soluble nature of the polymer, including its lower glass transition
temperature make them an appropriate choice as the drug and the carrier for HME processing at
relatively lower temperatures.
The nature of Kollidon® VA 64 as a matrix polymer in HME has been previously studied
by the researchers to some extent. Rapidly disintegrating tablets containing Indomethacin and
Kollidon® VA 64 extrudates were prepared by Dinunzio et al., and the authors studied the use of
Ceolus(™) microcrystalline cellulose in producing these tablets (31). In addition, Jijun et al. has
prepared the solid dispersion tablets of Nimodipine with a mixture of Eudragit ® EPO and
Kollidon® VA 64 by combining HME with direct compression, to improve its dissolution
behavior in different media (32). However, a further in-depth characterization of the Kollidon®
VA 64 hot melt extrudates involving the processing and formulation parameters is warranted for
a thorough understanding of the formed dispersion systems utilizing this polymer. Therefore, in
the current study, we have extensively studied the influence of various process parameters such
as screw speed and extrusion temperature, and formulation factors such as drug load, plasticizer
type and concentration on extrudability, drug release, and stability. In addition, the effect of
moisture on content uniformity and dissolution, and effect of extrusion on powder flow
characteristics have also been studied.
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2.2.Materials and Methods
2.2.1. Materials
Nifedipine USP was purchased from LETCO Medical (Decatur, AL, USA); polyethylene
glycol 3350, triethyl citrate, stearic acid, vitamin E succinate, propyl paraben, sodium lauryl
sulfate (SLS), potassium phosphate monobasic, and sodium hydroxide were obtained from
Fisher Scientific (Fair Lawn, NJ, USA). Kollidon® VA 64 was kindly gifted by BASF
Corporation. High performance liquid chromatography (HPLC) grade water was freshly
prepared in the laboratory by Nanopure systems (Barnstead, Dubuque, IA, USA). All solvents
utilized in the study were of analytical grade and obtained from Fisher Scientific (Fair Lawn, NJ,
USA).
2.2.2. Analytical Method
In-house reverse phase high performance liquid chromatography (HPLC) based
analytical method was developed for determination/quantification of NIF, and validated
according to ICH and FDA guidelines for chromatographic method. An HPLC equipped with
UV detector, Waters Symmetry shield 5μ C18 column (250×4.6 mm), and an isocratic mode of
elution with mobile phase containing acetonitrile and water (55:45) at a flow rate of 1.0 mL/min
were employed to quantify the drug at a wavelength (λmax) of 235 nm. The acquired data was
processed using Empower 2 build 2154 software (Waters Inc., Mount Holly, NJ, USA).
2.2.3. Solubility Parameter Calculations
Hansen solubility parameters were obtained from the literature, and for materials not
referenced in the literature were calculated based on their molecular structure and melting point
using Molecular Modeling Pro, v6.2.8 (ChemSW, Fairfield, CA).
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2.2.4. Thermal Gravimetric Analysis (TGA)
The thermal stability of the NIF, Kollidon® VA 64, their physical mixture and the melt
extruded samples was determined as a function of weight loss. The analysis was performed on
the samples (4-5 mg approximately) using a Perkin-Elmer Pyris 1 thermo-gravimetric analyzer
(Norwalk, CT) operated a ramp rate of 20°C/min from a temperature of 50°C to 250°C. The %
weight loss for all of the samples tested was recorded using the Pyris 1 TGA software. All of the
TGA runs were performed in an open pan with purge and protective nitrogen gas flow at 40
mL/min.
2.2.5. Differential Scanning Calorimetry (DSC) Analysis
DSC was used to characterize the miscibility of NIF in a polymeric carrier, Kollidon®
VA 64, utilizing a Perkin-Elmer Diamond DSC instrument (Shelton, CT). A 2-3 mg sample of
the pure drug and the polymer, and their physical mixtures with varying drug concentrations (5,
10, 20, 40, 60, and 80%) were weighed, sealed in aluminum crimped pans (Kit 0219-0062,
Perkin-Elmer Instruments, Shelton, CT), and heated from 40 to 245°C at a ramp rate of
20°C/min under nitrogen purge at a flow rate of 20 mL/min. The hot melt extrudates were
prepared by varying the drug concentrations as mentioned above, and subjected to an initial heatcool cycle (by heating to 140°C at the rate of 20°C/min and held for 5 min followed by cooling)
to remove the thermal history of the samples. A second heat cycle was initiated wherein the
samples were heated from 40 to 230°C at a ramp rate of 20°C/min under nitrogen purge at a flow
rate of 20 mL/min.
2.2.6. Hot Melt Extrusion (HME)
NIF and Kollidon® VA 64 were used as a model drug and carrier matrix, respectively.
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Prior to processing, required materials previously sieved through mesh # 40 were accurately
weighed, premixed in a mortar and pestle to get a homogeneous mixture. The resultant blend was
further mixed in a twin-shell dry V-blender (The Patterson-Kelly co., Inc. East Stroudsburg, PA)
at a speed of 25rpm for 10 minutes. Each of these resultant drug-polymer binary mixtures
containing 25% of the drug were extruded at three different temperature profiles (115, 135, and
155°C) utilizing a bench top co-rotating twin-screw hot melt extruder (Prism 16mm EuroLab,
Thermo Electron Corporation, Newington, NH) using 8 mm round opening die. Also, at each of
the temperature profiles three different screw speeds of 25, 50, and 100 rpm were employed and
a total of nine hot melt extrudates of the same formulation were obtained to study the effect of
process parameters. In addition, effect of processing aids and extrudates containing 10%/90%
w/w and 40%/60% w/w drug/polymer mixtures were produced utilizing HME to study the effect
of drug load. All of these final extrudates obtained were stored in foil-lined polyethylene bags
and stored in a refrigerator until further analysis.
2.2.6.1.Post-Processing Drug Content
A portion of all of these extruded formulations were crushed into fine powder using
mortar and pestle and stored in amber colored glass bottles. These processed and powdered
extrudates were analyzed for the drug content immediately after extrusion through the hot melt
extruder. A known amount of the extrudates and physical mixture were dissolved in 3:2
methanol: water, diluted and filtered using 0.2 µm, 13 mm PTFE membrane filters (Whatman,
Piscataway, NJ) and analyzed utilizing a HPLC at a wavelength of 235 nm.
2.2.7. X-Ray Diffraction (XRD) Testing
XRD testing was conducted using a Philips Model 1710 X-ray diffractometer (Philips
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Electronic Instruments Inc., Mahwah, NJ) to assess crystallinity in conjunction with thermal
techniques. Powders of the pure drug sample (NIF), the polymer (Kollidon® VA 64), physical
mixture, and the hot melt extrudates were passed through a # 40 mesh screen prior to the testing.
Physical mixtures were prepared by pre-mixing NIF and Kollidon® VA 64 in the appropriate
ratio (25% drug/75% polymer). Instrument was operated at an accelerating voltage of 40 kV and
30 mA. Samples of powder were placed into channeled stages and the diffraction profile was
measured from 3.0o to 50.0o using a 2θ step size of 0.02o and dwell time of 3s.
2.2.8. Moisture Absorption Study
In order to investigate the extent of moisture absorption by the drug, polymer, (1:3; drug:
polymer) physical mixture, and the hot melt extruded binary samples in the ratios of 1:9, 1:3, and
2:3 of drug: polymer produced by the previously described methods, each of the samples was
placed in a 40°C/75%RH environment, in opened amber colored borosilicate glass bottles for 7
days. In addition, the HME samples were also compared before and after moisture absorption for
content uniformity.
The moisture absorbed by the samples is reported in terms of their % weight gain and
was calculated by the following procedure. A sample of approximately 200 mg was weighed and
placed in opened amber glass bottles which were equilibrated at 40°C/75%RH. The % weight
gain (G) of samples was calculated using equation 3 provided below:
---------- Equation 3
Where

is the weight of the sample before moisture absorption,

glass bottle with sample (before moisture absorption) and

is the initial weight of a

is the final weight of a glass bottle

with sample (after moisture absorption). All measurements were performed in triplicate and were
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compared with the initial data.
2.2.9. Flow Properties
The pure polymer, drug-polymer physical mixtures with varying drug loads (10, 25 & 40%
w/w), and their corresponding extrudates have been assessed for their flow characteristics using
traditional “angle of repose” measurement. In this experiment, a funnel was set to a fixed height
using a clamp such that the distance between the lower tip of the funnel and the surface of a
graph paper placed below is constant. The powder was slowly poured through the funnel on to
the paper until the bulk material forms a conical pile, with its tip touching the base of the funnel.
The angle of repose for each of these powders was then measured by the equation 4 provided
below:
--------- Equation 4
In the above equation, ‘h’ is the height of the pile of powder, and‘d’ is the diameter of the
surface covered by the powder.
2.2.10. In vitro Dissolution Testing
Dissolution testing (USP XXXI, Apparatus I) was performed utilizing a Hanson SR8plus™ dissolution test station (Hanson Research Corporation, Chatsworth, CA) operated at 50
rpm paddle speed. Drug release from the formulations extruded by varying the process
parameters were evaluated for their release. Moreover, the effect of drug loaded samples (10%,
25%, and 40% w/w) were compared before and after moisture absorption for drug dissolution.
An amount equivalent to 25.0 mg NIF (theoretical drug loading) from the physical mixture and
the hot melt extrudates previously ground in mortar and pestle was accurately weighed and filled
in gelatin capsule # 3. These capsules were added to the dissolution vessel containing 900mL of

36

pH 6.8 phosphate buffer with 1% w/v sodium lauryl sulfate (SLS) preheated to 37°C. During
testing 1.5mL samples were removed from the dissolution vessels at pre-determined time
intervals and replaced with an equal volume of fresh dissolution medium. Samples were
immediately filtered using 13 mm PTFE membrane filters (Whatman, Piscataway, NJ) with a
pore size of 0.2 µm and analyzed using HPLC at a λmax of 235nm. Drug concentration was
calculated from a standard calibration plot and expressed as cumulative % drug dissolved. The
release studies were also performed in triplicate and the mean values were compared.
2.2.11. Stability Studies
A portion of NIF-Kollidon® VA 64 extrudates produced were stored in amber colored
borosilicate glass bottles at 3 different temperatures of 4, 25 and 40°C and analyzed at predetermined time intervals for the amount of NIF present using HPLC. The stability of these
extrudates was then compared to the physical mixture. The results of the stability studies are
expressed as a percentage of NIF degraded at various time intervals.
2.2.12. Statistical analysis
To compare between different formulations, statistical analysis was performed utilizing
one way analysis of variance (ANOVA). A statistically significant difference was considered
when P<0.05.
2.3.Results and Discussion
2.3.1. Analytical Method
Validation was carried out as per the ICH and FDA guidelines for the chromatographic
method development. The linear calibration range for the detection of NIF was found to be 5-200
μg/mL, with the co-efficient of determination (R2) of 0.999. The limit of detection and
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quantitation for the drug were 0.2 and 1.0 µg/mL, and the retention time for the NIF was ~7.8
minutes. The % relative standard deviation (RSD) within replicates (n=3) was less than 2%,
demonstrating reproducibility of the method. Precision was tested by injecting a single drug
concentration of 20μg/mL, and the peak area (n=10) was recorded. A superior precision was
observed with less than 0.5% of RSD.
2.3.2. Solubility Parameter Calculations
A three dimensional Hansen solubility parameter obtained from either literature or
Molecular Modeling ProTM software represents dispersive, polar and hydrogen bonding
interactions of a molecule, and it could be used to estimate the interactions amongst the
components in a formulation (33). From a pharmaceutical applications standpoint, this parameter
is a very useful tool in predicting the API morphology and drug-polymer miscibility in the solid
dispersions and the drug-excipient interactions in the development of solid oral dosage forms.
The effective solubility parameter obtained from Hansen method for NIF and Kollidon® VA 64
were 17.9 MPa1/2 and 21.1 MPa1/2, respectively. Theoretically, in order to observe at least partial
miscibility between the drug and the polymer, the solubility parameter difference (Δδ) between
them is required to be at least less than 7.0 MPa1/2 (34, 35). In the present scenario, Δδ is 3.2,
which is significantly less than 7.0 MPa1/2, indicating the NIF miscibility in the utilized carrier
matrix to form a solid dispersion.
2.3.3. Thermal Gravimetric Analysis
It is very crucial to study the thermal profiles of the active and the individual excipients
present in a formulation, prior to melt extrusion. In order to evaluate the active and excipients
processability and stability during extrusion, the materials were subjected to heat ramp and
identified that both, pure components and their physical mixture, exhibited less than 2% weight
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loss throughout the temperature range studied (Figure 2-1). Therefore, it has been concluded that
the processing temperatures under study are suitable to evaluate; however, it should be noted that
heat ramp was very quick in case of TGA study and the outcome of prolonged exposure of the
components to such high temperatures is not yet clear and requires further investigation.

Figure 2-1: An Overlay of Thermogravimetric Analysis Profiles of Nifedipine, Kollidon®
VA 64, 25% Nifedipine – 75% Kollidon® VA 64 Physical Mixture, and their Corresponding
Hot Melt Extrudates

2.3.4. Differential Scanning Calorimetry Analysis
Solid dispersion has been one of the promising approaches utilized to enhance the
dissolution rate of the poor-soluble actives. An important prerequisite to attain the solid
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dispersion formation is miscibility or interaction between the API and polymeric components in
a formulation. In the present study, the miscibility of NIF at various concentrations in Kollidon®
VA 64 carrier matrix was investigated using Perkin-Elmer diamond DSC. In the thermograms
shown in Figures 2-2A and 2-2B, temperature is plotted on the X-axis and heat flow (Endotherm
up) on the Y-axis. The DSC thermogram of the pure drug revealed a characteristic melting
endotherm of NIF at 172-174°C (36), while the physical mixtures exhibited a slight melting
point depression of the drug in presence of the polymer, indicating its miscibility in the carrier
matrix. NIF was completely miscible only at a concentration of 5% w/w in the physical mixtures,
whereas the hot melt extrudates demonstrated good miscibility of the drug (up to 40% w/w) in
the polymeric matrix. The peak corresponding to the melting of NIF was clearly evident in the
DSC thermogram of the physical mixtures at 40% w/w of the active, whereas it disappeared in
the melt extrudates (loss of crystallinity) at same drug load. This could be attributed to the
formation of an amorphous solid dispersion of NIF in the Kollidon® VA 64 matrix. However,
NIF at a concentration of 60% and 80% w/w in the melt extrudates does not seem to be
completely miscible.
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Figure 2-2: DSC Thermograms of (A) Pure Nifedipine, Kollidon® VA 64 and the
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Nifedipine/Kollidon® VA 64 Physical Mixtures with Varying Drug Loads, and (B) Pure
Nifedipine, Kollidon® VA 64 and the Nifedipine/Kollidon® VA 64 Hot Melt Extrudates with
Varying Drug Loads
2.3.5. Hot Melt Extrusion (HME)
2.3.5.1.Effect of processing parameters (Temperature and Screw speed)
The process parameters employed in the study are provided in Table 2-1. All of the
formulations exhibited a maximum die pressure of 6-7 bars, and the material feed rate was
consistent in each case. The extrudates processed at lower barrel temperatures (115 and 135°C),
irrespective of screw speeds, exhibited higher post-processing drug content (97-100%).
Table 2-1: Various Processing Parameters Employed, and Responses Observed During
HME
Extrusion Temperatures (deg C)

115

135

155

Extrusion Speeds (rpm)

25

50

100

Residence Time (min)

6 to 7

3 to 4

1 to 2

Observed Max Die Pressure

6 to7 bars

Torque Maintained

50%-60% - (12 - 15 Nm)

However, those processed at a higher extrusion temperature of 155°C, the postprocessing drug content decreased with decrease in screw speed from 100 to 25rpm (Figure 2-3).
In particular, the formulation produced at a higher temperature (155°C) and lower screw speed
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(25rpm) exhibited only 45% drug remaining, post-process. The lower screw speed of 25rpm
displayed relatively longer material residence time in the extruder barrel (approximately 6-7
minutes) in comparison to the higher screw speeds, and the exposure of the active at 155°C for
such a long period might have caused drug degradation. The results were in accordance with the
findings of Caira et al., where the authors identified an existence of a solvated crystal form of
NIF using single-crystal X-ray technique, which undergoes de-solvation leading to a complete
disruption of crystal structure and conversion into a thermo-sensitive monoclinic polymorph at
relatively high temperatures of 150-153°C (36). Both of the processing parameters, temperature
and screw speed, were found to have a significant impact on the post-processing drug content of
the final extrudates.

% Drug Remaining

100
80
60
40
20
0
25

50

100

Screw Speed (rpm)
115 degC

135 degC

155 degC

Figure 2-3: Effect of Processing Parameters on Post-Processing Drug Content in
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Nifedipine/Kollidon® VA 64 Hot Melt Extrudates. Data Represent Mean ± S.D (n=6)
2.3.5.2.Effect of formulation factors: Drug load and Process aids
It was identified from the process evaluation that use of lower temperatures was suitable
to produce reasonable extrudates with minimal drug degradation. Consequently, 10%, 25%, and
40% w/w NIF formulations were extruded at 135°C and 50rpm screw speed, which resulted in
formulations with excellent post-processing drug content (99-100%) in the formulations, with no
sign of drug degradation. The drug concentrations in the formulations were chosen based on the
results obtained from preliminary DSC studies that supported formation of solid dispersions in
mixtures comprising up to 40% w/w drug.
Furthermore, to produce a flexible formulation with greater ease and at lower
temperatures, processing aids are very essential. Kollidon® VA 64, as mentioned earlier, softens
above 100°C and may necessitate the use of a processing aid in order to produce a uniform melt
at relatively low process temperatures. For this purpose, several hydrophilic and hydrophobic
additives such as polyethylene glycol 3350, triethyl citrate, stearic acid, vitamin E succinate, and
propyl paraben, each at two different concentrations (2.5% and 5% w/w), were investigated as
process aids to evaluate their miscibility in drug-loaded Kollidon® VA 64 blend. Each of these
physical mixtures, in the preliminary set of experiments, containing 25% w/w drug, 70-72.5%
w/w of the polymer, and the processing aids was prepared into polymeric patches via casting
method on a heated brass plate at 130°C using a punch and 8 mm round die, and their properties
were observed visually for flexibility and texture. None of the chemical processing aids utilized
in the formulation exhibited flexibility in the melt casted films of the polymeric carrier.
Moreover, they produced either glassy or sticky products at the concentrations employed.
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Nevertheless, Kollidon® VA 64 was extrudable at 90% w/w, with only a model drug in the
formulation.
2.3.6. X-Ray Diffraction (XRD) Testing
DSC studies indicated the drug-polymer miscibility in the hot melt extruded formulations
(data not shown), which has been further confirmed by the XRD analysis. The diffraction pattern
of pure NIF exhibited sharp and highly intense peaks at 2θ degrees of 8.0, 11.9, 19.5, and 24.0,
indicating crystalline nature of the drug (37). However, the physical mixtures containing drug
and polymer at 1:3 ratios, when subjected to X-ray diffraction, exhibited relatively less intense
and more diffused peaks, but the 2θ angles of the peaks remained unaffected (Figure 2-4). These
changes in peak intensity could be attributed to the dilution of the active in the Kollidon® VA 64
matrix, and the unchanged 2θ angles of the peaks indicate existence of original crystalline form
of the drug in the physical mixture. On the contrary, XRD pattern of melt extruded formulations
produced using different process parameters did not demonstrate any sign of crystallinity or
characteristic peaks at specific 2θ angles, indicating formation of an amorphous solid dispersion
in those formulations. This data further strengthens the DSC results discussed earlier, where the
active was completely miscible in the melt extrudates up to 40%w/w with no sign of
characteristic melting endotherm of NIF.
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Figure 2-4: X-ray Diffraction Patterns of Nifedipine, Kollidon® VA 64, Drug/Polymer
Physical Mixture (1:3), and their Corresponding Melt Extruded Sample Produced at 135°C
and 50 rpm Screw Speed
2.3.7. Moisture Absorption Study
It was hypothesized that variability in the intimacy of mixing in different powder samples
would be explained by investigating the extent of moisture absorption, which is directly
proportional to the amount of hygroscopic surface area of the material being tested (38). Thus
extent of moisture absorption could be an indicative of the intimate mixing of powders, and high
moisture content in the powder mixtures could lead to inconsistency in the drug content and drug
dissolution. In the present study, the extent of moisture absorption is estimated by percentage
weight gained by the powder mixtures, when subjected to high relative humidity conditions.
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Although mixtures were exposed to high humidity conditions for 7 days, all of the samples under
test reached equilibrium within 24 hours. The hot melt extrudates (at 25% w/w drug loading)
exhibited 15-20% decrease in weight gain compared to their corresponding physical mixture, and
about 30% decrease in weight gain in comparison to the pure polymer, when subjected to the
same conditions. Amongst the hot melt extrudates, the formulations produced utilizing different
process temperatures and screw speeds did not demonstrate any significant difference in %
moisture absorbed (data not presented), indicated by unchanged percentage weight gain of the
mixtures. However, the weight gain in the milled extrudates decreased from 20% to 45% as the
drug concentration increased from 10% to 40% w/w, in comparison to the pure polymer (Figure
2-5). This decrease in the % weight gain or reduced moisture uptake could be attributed to the
presence of low concentrations of hygroscopic polymer in the formulations with higher drug
load.
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Figure 2-5: Moisture Absorption Study of Nifedipine, Kollidon® VA 64, Drug/Polymer
Physical Mixture (1:3), and the Milled Extrudate Samples Produced at Varying Drug
Loads. Data Represent Mean ± S.D (n=3)
Additionally, content uniformity of NIF in the milled hot melt extrudates containing 10%,
25% and 40% w/w drug loads, prior to and after exposure to high humidity conditions for a
period of 7 days was evaluated. From the data presented in Figure 2-6, it is obvious that the
milled extrudate samples did not show any great change in the drug content uniformity before
and after being exposed to high moisture environment, irrespective of their drug concentrations.
Although the % weight gain varied amongst milled extrudates with different drug loading, the
drug distribution within the polymeric mixtures was not affected by the presence of moisture.
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This could be due to the drug being uniformly distributed at a molecular level in the polymeric
matrix, during HME process, which provides intimate contact of both the components in a
formulation.

Figure 2-6: Content Uniformity of Nifedipine in the Milled Hot Melt Extrudates
Containing 10%, 25% and 40% W/W Drug Loads and in 25% Drug-75% Polymer
Physical Mixture Prior to, and After Exposure to High Humidity Conditions. Data
Represent Mean ± S.D (n=3)
2.3.8. Flow Properties
Manufacturing dosage forms such as tablets and capsules is very simple and costeffective approach that has been in practice over many decades. In order to produce such
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formulation with good content uniformity, it is essential to consider the powder characteristics
such as particle shape, density, coefficient of friction of the material etc. Angle of repose,
utilized to measure the flow properties, is also related to these attributes mentioned above.
Smaller angles correspond to wide spread of the bulk material, indicating better flow. From the
study results presented in Table 2-2, Kollidon® VA 64 demonstrated superior flow by itself.
However, an increase in the drug load from 10% w/w to 40% w/w in the physical mixtures
resulted in larger angles that indicate poor flow characteristics. This behavior could be attributed
to the difference in particle sizes between the API and the polymer, and to the cohesive nature of
API diluting the free flowing polymer.
Table 2-2: Flow Properties of the Drug-Polymer Mixtures before and after HME
Angle of Repose (θ)

Samples

Prior to Extrusion

Post Extrusion

PVPVA 64

21.95

--

10% Drug Load

30.66

23.85

25% Drug Load

37.88

24.32

40% Drug Load

39.21

23.50

On the contrary, similar binary physical mixtures when processed utilizing hot melt
extruder followed by milling into fine powder, demonstrated superior powder flow
characteristics independent of drug loading. A possible explanation for this observation could be
formation of a solid dispersion post-extrusion, as previously confirmed by DSC and XRD
studies, where drug dissolves at a molecular level in the hydrophilic polymer matrix resulting in
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changing the API physical properties. Based on the results, it is obvious that HME technique
could be utilized to enhance the flow characteristics of the bulk material that could potentially
minimize the content uniformity issues in conventional dosage forms. Furthermore, morphology
and physical properties of the active and other excipients chosen in a formulation would be
important in governing the flow characteristics.
2.3.9. In vitro Dissolution Testing
Dissolution testing of the melt extrudates in vitro is another important aspect that gives an
idea of how a formulation behaves in vivo in terms of drug release. All of the extruded
formulations produced at different screw speeds and temperatures had shown similar release
profiles; in addition, more than 90% of the drug was released within 1 hour from all of the
formulations tested (Figure 2-7A & 2-7B). Similarity factor ‘f2’ was utilized to compare the
dissolution profiles amongst different formulations (39), and was calculated using equation 5,
where ‘n’ is the total number of sampling intervals and ‘Rt’ and ‘Tt’ are cumulative % drug
released from reference and test formulations at any time interval ‘t.’
f2

50 log{[1

1
n

n

( Rt

Tt ) 2 ]

t 1
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0.5

100 } ---------- Equation 5

Figure 2-7: Dissolution Profiles of Nifedipine/Kollidon® VA 64 HME (A) Processed at
135°C- Effect of Processing Speeds; and (B) Processed at 100rpm Screw Speed- Effect of
Processing Temperatures. Data Represent Mean ± S.D (n=3)
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All of the obtained f2 values, when compared amongst the dissolution profiles, were
between 50 and 100 indicating that the drug release was similar for all of the formulations under
investigation. Similarly, extrudates with varying drug loads of 10, 25 and 40% w/w were

Cumulative % Drug Released

analyzed for the drug release, and their release patterns were presented in Figure 2-8.
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Figure 2-8: Drug Release from Nifedipine/Kollidon® VA 64 Hot Melt Extrudates
Containing Varying Drug Loads Produced at 135°C and 50rpm Screw Speed. Data
Represent Mean ± S.D (n=3)
The formulation containing 10% drug loading demonstrated a higher release rate
compared to 25%, followed by 40% w/w drug load. The extrudates with lower drug
concentration (10% w/w) behaved as an immediate release dosage form with more than 90% of
the drug being released within 20 minutes, while those containing 25% w/w NIF loading
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released the same within 60 minutes. Hence, it was obvious that the drug load has a greater
impact on the release of the drug, and could be especially attributed to the presence of more
amount of hydrophilic matrix, Kollidon® VA 64, in the solid dispersion formulations containing
10% w/w NIF. On the contrary, the hot melt extrudates containing 40% w/w NIF demonstrated
slower drug dissolution in comparison to the extrudates with lower drug loading, which could be
ascribed to the poor solubility and wettability of the active.
In addition, drug release from the extrudates with varying drug concentrations was
studied before and after subjecting to the moisture absorption study. There was no significant
difference observed in the release profiles (data not shown) before and after the moisture
absorption, at each of the drug loads tested. Moreover, release of NIF from the 25% w/w
extrudates was found to be different, and significantly superior (Figure 2-8) compared to its
corresponding 25% w/w physical mixture (f2=36.70). This is indicative of an improved drug
dissolution rate from the extrudates in comparison to their corresponding physical mixtures, due
to the formation of solid dispersion (previously evidenced by the DSC and XRD data) utilizing
HME technique.
2.3.10. Stability Studies
Achieving a stable formulation with minimal or no API degradation throughout the
product’s shelf-life is of paramount importance for any given dosage form. The conventional
dosage forms have several excipients incorporated in their formulations that lead to an increased
possibility of drug-excipient incompatibilities, resulting in drug degradation. On the contrary, hot
melt extrudates in the present study have only drug-polymer binary mixture, which minimizes
the risk of drug instability in the formulation. Additionally, it is also well known that temperature
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is a key factor that influences the reaction rates, and plays an important role in chemical
degradation (40). As per Arrhenius equation a pharmaceutical system under investigation, when
subjected to excessive thermal exposure undergoes accelerated degradation. However, Arrhenius
assumption may be often invalid because of the unexpected phase changes or adsorbed moisture.
Hence, it is advisable to use the lowest temperatures for the study that produces measurable
failure in allocated time. Considering the fact, the chemical stability of the extruded formulations
was studied by storing the samples at three different temperatures (4, 25 and 40°C) and analyzing
them for % active remaining in the extrudates, which represents the scale on Y-axis (Figure 2-9).
The API degradation in all of the formulations under study was found to be less than 5% for up
to 3 months (period of study). These results indicate that the produced extrudates were
chemically stable, and the processing conditions did not significantly impact the stability of NIF
present in the extrudates.
This data was further corroborated with the physical stability results. As previously
mentioned, elevated temperatures promote the reaction rate by lowering the activation energy.
Typical elevated storage temperature under practice for accelerated degradation of a
pharmaceutical system is 40°C. Therefore, the physical stability of the extrudates stored at this
temperature for three months was assessed for change in the crystallinity or amorphous nature of
the formed solid dispersions.
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Figure 2-9: Chemical Stability of Nifedipine/Kollidon® VA 64 Hot Melt Extrudates
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Different

Figure 10: XRD Patterns Indicating Physical Stability of Nifedipine/Kollidon® VA 64 Hot
Melt Extrudates Produced Utilizing Varying Processing Conditions, Stored at 40°C for a
Specific Period of Time
XRD patterns (Figure 2-10) of the extrudates under investigation did not demonstrate any
sign of crystallization after exposing to elevated temperature for such a long period, signifying
their physical stability. In addition, all of the extruded formulations with 10%, 25% and 40%
drug loading were also found to be physically and chemically stable up to 3 months (data not
presented) under employed conditions.
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2.4.Conclusions
In this study, melt extrusion technique in combination with Kollidon® VA 64 produced
stable extrudates with higher drug loading and superior drug release. NIF was found to be
miscible in Kollidon® VA 64 up to 40% w/w drug load, without having need of any processing
aid for extrusion. Kollidon® VA 64, on the other hand, was extrudable at 90% w/w with only a
model drug in the formulation. The processing parameters had a significant impact on the postprocessing drug content, and the influence of drug load on release from extrudates was
remarkable. These results demonstrate the importance of selecting appropriate carrier matrix for
HME process, and utilizing suitable formulation and process conditions based on
physicochemical properties of the active and the polymeric carrier under study, which could
greatly influence the final properties of the produced extrudates.
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CHAPTER - 3
Characterization of Soluplus® Hot Melt Extrudates: Effect of Formulation and Process
Parameters on Miscibility, Dissolution and Stability Characteristics

3.1.Introduction
Advent of high throughput screening and combinatorial chemistry is resulting in more
complex API (active pharmaceutical ingredient) structures. It has been estimated that 40-50% of
all new molecular entities suffer from poor bioavailability due to low aqueous solubility (16).
Formulation of such compounds for oral delivery presents one of the most frequent and
formidable challenges to formulation scientists. Numerous techniques such as spray drying,
solvent-evaporation, nano-crystal formation, complexation, and micronization of API etc., have
been widely utilized in the industry to demonstrate the improved solubility and/or dissolution
rate of such drugs, thereby enhancing their bioavailability (23-27). In addition, over the past
couple of decades, HME technique has gained enormous interest amongst researchers in
improving the bioavailability of drug substances, especially those having low water solubility, by
formation of molecular dispersions (13, 14, 16, 17). HME offers several advantages such as
being solvent free and involving fewer processing steps in comparison to other techniques.
As mentioned earlier, HME is the process of pumping raw materials with a rotating screw
under elevated temperature through a die into a product of uniform shape. These final extrudates
obtained utilizing thermal energy may be in the form of films or rods that can be cut as tablets or
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pellets. To date, several research papers have been published by scientists that focused on the
preparation of solid dispersions/solutions of numerous poorly aqueous soluble model drugs such
as CTZ, indomethacin and NIF etc. utilizing HME technique. In addition, different grades of
hydrophilic and hydrophobic polymers such as PolyOx™, Eudragit®, Kollidon®, Ethocel® were
utilized to produce such dispersions, and were characterized in-depth using HME technique.
Soluplus®, a recently introduced polymer, is mainly employed as the carrier matrix in the
current study. Soluplus® is a graft copolymer of PEG 6000/vinyl caprolactam/vinyl acetate
copolymer in 13/57/30 ratios. It is white to yellowish free flowing granules with a glass
transition temperature at ~70°C. The high flowability combined with its good extrudability
characteristics demonstrate an excellent performance of the polymer in the formation of solid
solutions, especially in HME processes. Due to the presence of PEG 6000, it is believed to have
solubilization effect as well. Therefore, Soluplus® combines the benefits of solid solutions and
solubilization which thereby increases solubility of poorly soluble drugs and hence enhance
bioavailability. The properties mentioned above makes Soluplus® an attractive carrier matrix for
HME processing, but to date, there is little research published on Soluplus® and needs further
evaluation.
Lust et al. studied the formation of piroxicam solid dispersions using Soluplus® as the
carrier matrix. The authors concluded that Soluplus® enhanced the dissolution as well as the oral
bioavailability of piroxicam in rats (41). Solid dispersions of various drugs such as
indomethacin, famotidine, camptothecin, and fenofibrate were also produced using this
polymeric solubulizer, Soluplus® (42-44). It is also been used in the preparation of bicalutamide
nano-crystals which are produced by anti-solvent precipitation method (45). In addition, it is also
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used as a carrier matrix in the preparation of carbamazepine-nicotinamide co-crystals (46). Apart
from being used as a carrier matrix in HME, Soluplus® has also been used in the electro-spinning
and KinetiSol® dispersing techniques as well (47, 48).
In addition, many research scientists have also published the effect of process parameters
during extrusion. Few examples are: Shibata et al. produced solid solution of Indomethacin and
crospovidone using twin-screw extruder, and demonstrated that the parameters such as residence
time, screw speed, and heating temperature play a significant role in the extrusion process (28).
On the contrary, in a study by Verhoeven et al., the effect of process parameters (Screw design,
feed rate and screw speed) on metoprolol tartarate and ethyl cellulose mini matrices were
studied, and revealed that the process parameters had no significant influence on drug quality as
well as drug release, indicating robustness of HME technique (29). In addition, the role of
kneading paddle elements and operating conditions of twin screw extruder on NIF and HPMCP
extrudates were studied by Nakamichi et al., and concluded that all of these factors played an
important role in obtaining ideal solid dispersions (30). Most of these previous studies reveal that
the influence of process parameters primarily depends on multiple factors such as the API
involved, the carrier matrix utilized, and the processing conditions employed during the HME
process.
Therefore, in the current study, CTZ was utilized as a model drug, which is a practically
water-insoluble antifungal agent with a melting point of 146-147°C, and Soluplus® was used as a
polymeric matrix to further investigate the feasibility of producing drug-loaded Soluplus®
extrudates. Solid dispersions in the present study were produced using a MiniLab II HAAKE
Rheomex CTW5 (conical twin-screw compounder) manufactured by ThermoFisher Scientific. In
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early drug development stages, very less quantities of drug is available to conduct the feasibility
studies. In such circumstances, this kind of equipment is well suited as the minimum quantity
required for this extruder is only 5-10 gm. This manuscript illustrates the readers the effect of
formulation and process parameters such as drug load and drug residence time on a much smaller
scale, especially, when small amount of the drug is available. The influence of formulation and
processing parameters such as drug-load and residence time, respectively, on the drug-polymer
miscibility and drug release was also studied, including the physical and chemical stability of
these extrudates.
3.2.Materials and Methods
3.2.1. Materials
Clotrimazole USP was purchased from LETCO Medical (Decatur, AL, USA);
Hydrochloric acid was obtained from Fisher Scientific (Fair Lawn, NJ, USA). Soluplus® was
kindly gifted by BASF Corporation. High performance liquid chromatography (HPLC) grade
water was freshly prepared in the laboratory by Nanopure systems (Barnstead, Dubuque, IA,
USA). All solvents utilized in the study were of analytical grade and obtained from Fisher
Scientific (Fair Lawn, NJ, USA).
3.2.2. HPLC Analysis
In-house reverse phase high performance liquid chromatography (HPLC) based
analytical method was developed for determination/quantification of CTZ. An HPLC equipped
with UV detector, Novapak phenyl column (150×4.6 mm) with particle size of 3μ, and an
isocratic mode of elution with mobile phase containing methanol and 25mM KH2PO4 buffer
(80:20) at a flow rate of 1.0 mL/min were employed to quantify the drug at a wavelength (λmax)
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of 215 nm. All injections were performed by an autosampler, and the injection volume was
20µL. The acquired data was processed using Empower 2 build 2154 software (Waters Inc.,
Mount Holly, NJ, USA).
3.2.3. Thermal Gravimetric Analysis (TGA)
The thermal stability of the CTZ, soluplus®, and their physical mixture samples was
determined as a function of weight loss. The analysis was performed on the samples (4-5 mg
approximately) using a Perkin-Elmer Pyris 1 thermo-gravimetric analyzer (Norwalk, CT)
operated at a ramp rate of 20°C/min from a temperature of 40°C to 250°C. The % weight loss for
all of the samples tested was recorded using the Pyris 1 TGA software. All of the TGA runs were
performed in an open pan with purge and protective nitrogen gas flow at 40 mL/min.
3.2.4. Differential Scanning Calorimetry (DSC) Analysis
DSC was used to characterize the miscibility of CTZ in a polymeric carrier, soluplus®,
utilizing a Perkin-Elmer Diamond DSC instrument (Shelton, CT). A 2-3 mg sample of the drug,
polymer, and physical mixtures with varying drug concentrations (10, 20, 30, 40, and 50%) were
weighed, sealed in aluminum crimped pans (Kit 0219-0062, Perkin-Elmer Instruments, Shelton,
CT), and heated from 30 to 210°C at a ramp rate of 20°C/min under nitrogen purge at a flow rate
of 20 mL/min. The hot melt extruded samples were subjected to an initial heat-cool cycle (by
heating up to 130°C at the rate of 20°C/min and held for 5 min followed by cooling) to remove
the thermal history of the samples. A second heat cycle was initiated wherein the samples were
heated from 40 to 210°C at a ramp rate of 20°C/min under nitrogen purge at a flow rate of 20
mL/min. In addition, the extruded samples with 30% drug load were subjected to prolonged heat
exposure (varying residence time of 1, 5, and 10 min) at a barrel temperature of 130°C, and their
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thermal characteristics were also studied.
3.2.5. Hot Melt Extrusion (HME)
CTZ and soluplus® were used as a model drug and carrier matrix, respectively. Prior to
processing, required materials previously sieved through mesh # 40 were accurately weighed and
were further blended in a twin-shell dry V-blender (The Patterson-Kelly co., Inc. East
Stroudsburg, PA) at a speed of 25rpm for 10 minutes. The CTZ-Soluplus® binary mixtures
containing 10%, 20% and 30% of the drug load were extruded at 130°C and 70 rpm screw speed
utilizing a conical twin screw compounder (MiniLab II HAAKE Rheomex CTW5, ThermoFisher
Scientific). The torque (N-cm) and the pressure difference (ΔP) generated during the extrusion
process were recorded.
In addition, to assess the effect of processing time, each of the above produced
formulations were exposed at 130°C for 1, 5 and 10 minutes. All of these final extrudates
obtained at each of the mentioned conditions were stored in foil-lined polyethylene bags and
stored in a refrigerator until further analysis.
3.2.5.1.Post-processing Drug Content
A portion of all of these extruded formulations were crushed into fine powder using
mortar and pestle and stored in amber colored glass bottles. These processed and powdered
extrudates were analyzed for the drug content immediately after extrusion through the hot melt
extruder. A known amount of the extrudates and physical mixture were dissolved in 4:1
methanol: water, diluted and filtered using 0.2 µm, 13 mm PTFE membrane filters (Whatman,
Piscataway, NJ) and analyzed utilizing a HPLC at a wavelength of 215 nm.
3.2.6. Fourier-transform infrared spectroscopy
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FTIR spectra for the drug, polymer, and their extrudates produced with varying drug
loads were obtained using a Perkin Elmer FTIR spectrometer (PerkinElmer Life and Analytical
Sciences, Shelton, CT, USA). A spectrum was collected for each sample within the wave number
region 4,000-400 cm−1. The spectra were analyzed for the absence or shift in the wave numbers
of the characteristic peaks and reported.
3.2.7. In vitro Dissolution Testing
Dissolution testing (USP XXXI, Apparatus II) was performed utilizing a Hanson SR8plus™ dissolution test station (Hanson Research Corporation, Chatsworth, CA) operated at 50
rpm paddle speed. Drug release from the formulations extruded at varying CTZ loads (10%,
20%, and 30% w/w) were evaluated for their release. Moreover, the effect of residence time (1,
5, and 10 minutes) on drug release from extrudates containing 30% CTZ was studied. A 60mg
sample from each of the produced melt extruded formulations, previously ground in mortar and
pestle, was accurately weighed and filled in gelatin capsule # 4. These capsules were added to
the dissolution vessel containing 900mL of 0.1N hydrochloric acid (pH 1.2) preheated to 37°C.
During testing 1.5mL samples were removed from the dissolution vessels at pre-determined time
intervals and replaced with an equal volume of fresh dissolution medium. Samples were
immediately filtered using 13 mm PTFE membrane filters (Whatman, Piscataway, NJ) with a
pore size of 0.2 µm and analyzed using HPLC at a λmax of 215nm. Drug concentration was
calculated from a standard calibration plot and expressed as cumulative % drug dissolved. The
release studies were also performed in triplicate and the mean values were compared.
3.2.8. Stability Studies
A portion of CTZ-soluplus® extrudates produced were stored in amber colored
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borosilicate glass bottles at 3 different temperatures of 4, 25 and 40°C and analyzed at predetermined time intervals for the amount of CTZ present using HPLC. The chemical stability of
these extrudates was then compared to the physical stability of the same assessed utilizing DSC
after 3-month time point. The results of the chemical stability studies are expressed as a
percentage of CTZ remaining at various conditions under investigation.
3.2.9. Statistical analysis
To compare between different formulations, statistical analysis was performed utilizing
one-way analysis of variance (ANOVA). A statistically significant difference was considered
when P<0.05.
3.3.Results and Discussion
CTZ is an antifungal compound that acts primarily by altering the permeability of the cell
wall and inhibiting the synthesis of ergosterol, which is required for the production of fungal cell
membrane. This active has very poor aqueous solubility characteristics with erratic oral
absorption, and therefore presents itself as a good candidate for HME processing to demonstrate
an enhancement in its dissolution characteristics. Soluplus®, on the other hand, is a hydrophilic
polymer that also exhibit solubilization capacity of poorly soluble drugs.
As a part of pre-formulation studies, TGA was performed to demonstrate the heat
stability and thermal processability of the drug and the polymer during melt extrusion process.
The TGA studies revealed that Soluplus® and CTZ were found to be stable under employed
extrusion conditions with about 2% weight change being observed (Figure 3-1), when heated up
to 250°C. An initial small decrease in the weights of the pure polymer and its corresponding 10%
drug physical mixture at about 100°C could be due to the loss of water from the Soluplus®.
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Figure 3-1: An Overlay of Thermogravimetric Analysis Profiles of Clotrimazole (CTZ),
Soluplus®, and 10% CTZ – 90% Soluplus® Physical Mixture
It was evident from the DSC studies of the physical mixtures that CTZ exhibited a
melting endotherm at all of the studied concentrations, which indicates that the drug’s
crystallinity is retained up on physical mixing with the polymer. However, a melting point
depression of the drug was noticed in the presence of the polymer (Figure 3-2).
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Figure 3-2: DSC Thermograms of Pure Clotrimazole (CTZ) and the CTZ/Soluplus®
Physical Mixtures at Varying Drug Concentrations
In the present research, drug was extruded with polymer alone at different concentrations,
without utilizing any of the processing aids. During the extrusion process both of the recorded
responses, torque and pressure, decreased with an increase in the drug concentration. The data
presented in Table 3-1 could be attributed to the plasticization effect of CTZ on Soluplus®.
Additionally, the 30% w/w CTZ-soluplus® binary blends were subsequently exposed to barrel
temperature for 1, 5, and 10 min, to further evaluate the effect of residence time. All of the
produced extrudates exhibited very good post-processing drug content with a mean and relative
standard deviation of 98.0% and 3.0%, respectively.
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Table 3-1: Responses Observed During Melt Extrusion Processing of Clotrimazole at
Different Drug Loads

Drug Load

Torque (N-cm)

∆P (bar)

10%

72

37

20%

60

16

30%

37

8

The DSC thermograms of the extrudates demonstrated drug miscibility up to 20% w/w,
when processed for one minute at a barrel temperature of 130°C. The higher drug loads
demonstrated a characteristic melting peak of the drug around 144°C (Figure 3-3). Interestingly,
the drug’s melting peak disappeared in 30% w/w extrudates obtained by exposure at 130°C for
10 minutes in comparison to those produced by 1 and 5 minutes exposure at the same
temperature conditions (data not shown). As the time of drug exposure to heat increased,
complete drug-polymer miscibility was observed at 30% w/w drug load.
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Figure 3-3: DSC Thermograms of CTZ/Soluplus® Hot Melt Extrudates: Effect of Drug
Load

FT-IR spectroscopic analysis was performed on the extruded samples to study the drugpolymer interactions, and to corroborate the miscibility results obtained by DSC. The spectra of
CTZ exhibit characteristic peaks at 3169 and 3042 cm-1 (aromatic C-H stretching), 1585, 1487
and 1305 cm-1 (benzene ring stretching), 1203 cm-1 (C-N stretching), and 1084 cm-1
(chlorobenzene stretching). The FTIR spectra of the extruded formulations presented in Table 32 and Figure 3-4 demonstrate the presence of CTZ characteristic peaks, indicating the absence of
any chemical interactions between the drug and the polymer.
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Table 3-2: Characteristic Peaks in the FTIR Spectra of Clotrimazole (CTZ) in Different
Hot Melt Extruded Formulations

Formulations

Aromatic C-H
Stretching (3169
& 3042 cm-1)

Benzene ring
Stretching (1585,
1487 & 1305 cm1
)

C-N
Stretching
(1203 cm-1)

Chlorobenzene
(1084 cm-1)

10% CTZ

√

√

√

√

20% CTZ

√

√

√

√

30% CTZ

√

√

√

√

30% CTZ-5min

√

√

√

√

30% CTZ-10min

√

√

√

√

Note: “√” indicates presence of the characteristic peak
Dissolution studies were conducted on the produced HME formulations to evaluate the
enhanced drug release from the produced solid dispersions. Over 90% of CTZ was released in
the first hour for the formulations containing 10% drug load. 10% CTZ-loaded matrices
exhibited faster release followed by 20% and 30% w/w. This slower release could be attributed
to the increasing concentration of hydrophobic drug from 10% to 30% in the extrudates. Drug
load, however, did not have any significant impact on the release of formulations containing 10%
and 20% CTZ (evident from ‘f2’ values presented in Table 3-3) since the crystalline CTZ was
completely converted into an amorphous form in 10% and 20% drug loaded extrudates.
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Figure 3-4: FTIR Spectra of Clotrimazole, Soluplus®, and Melt Extruded Formulations:
(A) Effect of Drug Load; (B) Effect of Residence Time. The Colored Spectra are
Represented as Follows: Black - Soluplus®; Blue – Clotrimazole (CTZ); Red – 10% CTZ
HME; Green – 20% CTZ HME; Maroon – 30% CTZ-1min; Pink – 30% CTZ-5min; and
Cyan – 30% CTZ-10min
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Table 3-3: Comparison of Dissolution Profiles Utilizing Calculated ‘Similarity Factor’
Values Between Different Melt Extruded Formulations
‘f2’ factor

Formulations
Direct Flush - Drug Load Effect
10%CTZ Vs 20%CTZ

56.1

10%CTZ Vs 30%CTZ

31.2

20%CTZ Vs 30%CTZ

39.2

30% CTZ - Residence Time Effect
CTZ 1min Vs CTZ 5 min

55.6

CTZ 1min Vs CTZ 10 min

29.1

CTZ 5min Vs CTZ 10 min

36.2

Alternatively, the 30% drug loaded extrudates demonstrated a significantly slower release
rate compared to 10% and 20% w/w drug loaded extrudates which can be attributed to the
presence of crystalline drug in the higher drug loaded extrudates (Figure 3-5A). Moreover, the
extrudates with 30% w/w drug load, when exposed at 130°C for 10 min in extrusion barrel did
demonstrate a significantly faster release compared to the other formulations extruded after 1 and
5 min exposure times at 130°C (Figure 3-5B). This is due to the formation of amorphous CTZ in
the extrudates produced (data supported by DSC), when exposed to the set temperature for a
longer duration (10 min).
Stability is another important aspect of any formulation in the drug development cycle. In
the current study, produced melt extruded formulations were subjected to both, physical (Figure
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3-6A) and chemical stability (Figure 3-6B). The samples stored at three different temperatures
were tested for crystallization of drug and found that the extruded formulations which formed
amorphous dispersions initially have remained same and did not demonstrate any sign of recrystallization during the storage period of three months. Similarly, the drug content of the
initially formed extrudates remained between 96-103% at the end of three months, indicating
chemical stability of the drug.
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Figure 3-5: Clotrimazole Release from Hot Melt Extruded Formulations: (A) Effect of
Drug Load; (B) Effect of Residence Time. Data Represent Mean ± S.D (n=3)
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Figure 3-6: (A) Physical Stability Obtained from DSC Thermograms and; (B) Chemical
Stability Obtained Utilizing HPLC Analysis of the Clotrimazole-Soluplus® Extrudates.
Chemical Stability Data Represent Mean ± S.D (n=3)
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3.4.Conclusion
CTZ was found to be miscible in Soluplus® up to 20% and 30% when processed for 1 min and
10min, respectively. Both formulation and process parameters, namely drug load and residence
time of the binary mixture had a significant impact on the drug-polymer miscibility in the final
extrudates which was confirmed by DSC and FTIR Studies. In addition, both, the drug load and
residence time also had a significant impact on the CTZ release from the melt extrudates. At a
relatively lower drug loads, complete solubilization of CTZ in Soluplus® was noticed. At the
higher drug concentrations of CTZ (30% w/w drug load), an increase in the residence time of the
formulation in the extrusion barrel aids in CTZ solubilization. The hydrophilic polymer,
soluplus®, also combines the benefits of solid solutions and solubilization to further increase the
dissolution rate of poorly soluble drugs. CTZ forms an amorphous solid dispersion within the
soluplus® matrix, and the melt extrudates containing up to 30% drug load were found to be
physically and chemically stable for a period of 3 months. Moreover, soluplus® was extrudable at
90% w/w with only a model drug in the formulation. The characteristics associated with this
relatively new polymer such as hydrophilicity and low glass transition temperature, along with
its ease of extrusion and additional solubilization capacity (due to polyethylene glycol) makes it
more appealing for utilization as a carrier matrix with myriad actives in HME processing.
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CHAPTER - 4
Characterization of Soluplus® Hot Melt Extrudates: Effect of Formulation and Process
Parameters on Miscibility, Dissolution and Stability Characteristics

4.1. Introduction
Curcumin is a safe, affordable and natural bioactive molecule of turmeric (Curcuma
longa). It is a bright yellow colored natural product, practically insoluble in water at acidic and
neutral pH, and soluble in alkali. This compound has gained considerable attention in recent
years for its multiple pharmacological activities such as anti-inflammatory (49), anti-oxidant (50,
51), anti-microbial (52), anti-cancer (53), anti-diabetic (54), and as a neuroprotective agent (55,
56). In spite of its several potential therapeutic advantages, its optimum pharmaceutical potential
has been limited by its lack of aqueous solubility and poor bioavailability (57, 58). To mitigate
the above limitations research has been performed over the years to improve the solubility of
curcumin utilizing nanocarriers, cyclodextrins (via complexation), carriers such as solutol® HS
15 (via solid dispersions) and surfactants (via micellar solubilization) (59-63).
Paradkar et al. has produced solid dispersion of curcumin and polyvinyl pyrrolidone
utilizing spray drying technique (23). The authors demonstrated formation of a high energy
amorphous phase and increased dissolution rate of curcumin from the produced solid dispersion
when compared to their corresponding physical mixtures. In another study, Wu et al. utilized
surfactants and appropriate solvents to produce self-microemulsifying drug delivery systems to
78

improve curcumin dissolution and bioavailability (64). Drug release from the formulation was
completed within 10 minutes. The developed SMEDDS formulation improved the oral
bioavailability of curcumin significantly, and the relative oral bioavailability of SMEDDS
compared with curcumin suspension was 1213%. Recently, Bansal and co-workers produced
curcumin implants using poly(ε-caprolactone) and HME technique (65). The data from the study
showed that these implants were able to release curcumin for long duration and to modulate liver
phase I and phase II enzymes, demonstrating curcumin’s biological efficacy delivered via this
delivery system.
Numerous research reports have been published on the use of hydrophilic polymers in
producing solid dispersions to enhance dissolution rate of poorly soluble drugs. Soluplus® is one
of the novel polymers comprising of PEG 6000, vinylcaprolactam and vinyl acetate in the ratios
of 13, 57, and 30, respectively. It is white yellowish free flowing granules with a glass transition
temperature of 69°C. When extruded, it combines the benefits of both solubilization and
formation of solid solutions to enhance the bioavailability of poorly soluble drugs (66).
Surfactants, on the other hand, are also widely used solubilizing agents in many pharmaceutical
dosage forms. These surfactants when used at appropriate levels form the micellar systems in
which the poorly soluble drugs are encapsulated and form a more soluble system. In this study,
we chose three different types of surfactants mainly classified based on their charge: cationic
(Cetyltrimethyl ammonium bromide-CTAB), anionic (Sodium lauryl sulfate-SLS) and non-ionic
(Pluronic® F127) surfactants. Additionally, each of these surfactants was evaluated at three
different concentrations to study their influence on drug release from the produced hot-melt
extrudates.
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Currently there are no available marketed formulations for curcumin as it exhibits
solubility-limited poor oral bioavailability. In addition, there is no research reported utilizing
combination of both, surfactants and HME. Therefore, in our current research, we attempted to
formulate a solubilized curcumin oral dosage form with enhanced dissolution characteristics, and
a high potential to demonstrate superior bioavailability utilizing a novel carrier, soluplus®,
suitable surface active agents, and HME technology. The objective of this study was to
investigate the feasibility of producing Soluplus®-Curcumin drug-loaded extrudates utilizing hotmelt extrusion (HME) technology. In addition, drug-polymer miscibility studies, including the
influence of charge and concentration of the utilized surfactants on dissolution rate of this poorly
water-soluble model drug were also investigated.
4.2. Materials & Methods
4.2.1. Materials
Curcumin, CTAB, SLS, and Pluronic® F127 were purchased from Fisher Scientific (Fair
Lawn, NJ, USA). Soluplus® was kindly gifted by BASF Corporation. High performance liquid
chromatography (HPLC) grade water was freshly prepared in the laboratory by Nanopure
systems (Barnstead, Dubuque, IA, USA). All other solvents utilized in the study were of
analytical grade and obtained from Fisher Scientific (Fair Lawn, NJ, USA).
4.2.2. Analytical Method
In-house reverse phase high performance liquid chromatography (HPLC) based
analytical method was developed for determination/quantification of curcumin, and validated
according to ICH and FDA guidelines for chromatographic method. An HPLC equipped with
UV detector, Waters symmetry shield 5μ C18 column (250×4.6 mm), and an isocratic mode of
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elution with mobile phase containing acetonitrile and 2% acetic acid solution in water (48:52) at
a flow rate of 2.0 mL/min were employed to quantify the drug at a wavelength (λmax) of 425
nm. The pH of the mobile phase is adjusted to 3.9, and the column temperature was maintained
around 33°C. The acquired data was processed using Empower 2 build 2154 software (Waters
Inc., Mount Holly, NJ, USA).
4.2.3. Thermal Gravimetric Analysis (TGA)
The thermal stability of the curcumin, and soluplus® samples was determined as a
function of weight loss. The analysis was performed on the samples (4-5 mg approximately)
using a Perkin-Elmer Pyris 1 thermo-gravimetric analyzer (Norwalk, CT) operated at a ramp rate
of 20°C/min from a temperature of 40°C to 250°C. The % weight loss for both the samples
tested was recorded using the Pyris 1 TGA software. All of the TGA runs were performed in an
open pan with purge and protective nitrogen gas flow at 40 mL/min.
4.2.4. Differential Scanning Calorimetry (DSC) Analysis
DSC was used to characterize the miscibility of curcumin in a polymeric carrier,
soluplus®, utilizing a Perkin-Elmer Diamond DSC instrument (Shelton, CT). A 2-3 mg sample of
the drug, polymer, and physical mixtures with varying drug concentrations (10, 20, 30, 40, and
50%) were weighed and sealed in aluminum crimped pans (Kit 0219-0062, Perkin-Elmer
Instruments, Shelton, CT). The physical mixture containing samples were subjected to an initial
heat-cool cycle (by heating up to 230°C at the rate of 20°C/min, followed by immediate cooling)
to remove the thermal history of the samples. A second heat cycle was initiated wherein the
samples were reheated from 30 to 250°C at a ramp rate of 20°C/min under nitrogen purge at a
flow rate of 20 mL/min. On the other hand, the melt extruded samples containing surfactants at
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varying concentrations were subjected to a single heating cycle from 30 to 250°C at a ramp rate
of 20°C/min.
4.2.5. Hot Melt Extrusion
Curcumin and soluplus® were used as a model drug and carrier matrix, respectively. Prior
to processing, required materials previously sieved through mesh # 40 were accurately weighed
and were further blended in a twin-shell dry V-blender (The Patterson-Kelly co., Inc. East
Stroudsburg, PA) at a speed of 25rpm for 10 minutes. Each of the formulations contained 30%
Curcumin (99% purity), Soluplus® (60 – 67.5%), and a surfactant (SLS, CTAB, and/or Pluronic®
F127), each at three different concentrations - 2.5%, 5%, and 10% w/w. These formulations were
extruded utilizing a conical twin-screw compounder (MiniLab II HAAKE Rheomex CTW5,
ThermoFisher Scientific) at 155°C and 70rpm screw speed. All of these final extrudates obtained
were stored in foil-lined polyethylene bags and stored in a refrigerator until further analysis.
4.2.5.1.Post-Processing Drug Content
A portion of all of these extruded formulations were crushed into fine powder using
mortar and pestle and stored in amber colored glass bottles. These processed and powdered
extrudates were analyzed for the drug content immediately after extrusion through the hot melt
extruder. A known amount (20 mg) of the extrudates and physical mixture were dissolved in
100mL of acetonitrile and filtered using 0.2 µm, 13 mm PTFE membrane filters (Whatman,
Piscataway, NJ) and analyzed utilizing a HPLC at a wavelength of 425 nm.
4.2.6. Drug Release Testing
Dissolution testing (USP XXXI, Apparatus II) was carried out utilizing a Hanson SR8plus™ dissolution test station (Hanson Research Corporation, Chatsworth, CA) operated at 75
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rpm paddle speed. The effect of surfactant type and concentration on drug release from
extrudates containing 30% curcumin was studied. A sample weight containing curcumin
equivalent to 100mg from each of the produced melt extruded formulations, previously ground in
mortar and pestle, was accurately weighed and filled in gelatin capsule # 1. These capsules were
added to the dissolution vessel containing 900mL of 0.5% w/w of SLS preheated to 37°C.
During testing 1.5mL samples were removed from the dissolution vessels at pre-determined time
intervals and replaced with an equal volume of fresh dissolution medium. The extruded
formulation containing no surfactant, and the drug release from pure curcumin powder were
utilized as controls. All of the samples were immediately filtered using 13 mm PTFE membrane
filters (Whatman, Piscataway, NJ) with a pore size of 0.2 µm and analyzed using HPLC at a
λmax of 425nm. Drug concentration was calculated from a standard calibration plot and
expressed as cumulative % drug dissolved. The drug release from all of the melt extrudates and
the pure drug were compared. The release studies were performed in triplicate and the mean
values were compared.
4.3. Results & Discussion
The TGA studies (data not shown) revealed that Soluplus® and Curcumin were stable
under employed extrusion temperatures. Hence, the formulations under study were extruded
utilizing a conical twin-screw compounder (MiniLab II HAAKE Rheomex CTW5,
ThermoFisher Scientific) at 155°C and 70rpm screw speed. Each of the formulations contained
30% curcumin (99% purity), soluplus® (60 – 67.5%), and a surfactant (SLS, CTAB, and/or
Pluronic® F127), each at three different concentrations - 2.5%, 5%, and 10% w/w. The postprocessing content results are presented in Figure 4-1. All of the produced formulations under
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employed extrusion conditions exhibited a higher post-processing drug content (97-100%) with
tighter standard deviation (<3%), indicating a robust formulation and process.

Figure 4-1: Post-Processing Drug Content of Curcumin Melt Extrudates

The DSC studies revealed that Curcumin exhibited an onset of melting endotherm at
around 172°C. The drug’s melting peak was visible in the physical mixtures (up to 50% w/w of
drug) during the first heating cycle (Figure 4-2A), which disappeared following the second
heating cycle. However, all of the produced extrudates did not demonstrate any melting
84

endotherm corresponding to curcumin, polymer, and/or the surfactants employed even during the
first heating cycle. The thermograms of all of the extruded formulations (Figures 4-2B to 4-2D)
demonstrated a single phase system, indicating an excellent miscibility of 30% Curcumin in the
Soluplus® matrix.
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Figure 4-2: Curcumin-Soluplus® Miscibility Studies – (A) Comparative Study of the DrugPolymer Physical Mixtures with Increased Drug Loading; (B) SLS HME Formulations
with 30% Curcumin; (C) CTAB HME Formulations with 30% Curcumin; and (D)
Pluronic® F127 HME Formulations with 30% Curcumin

It is also anticipated that the formed high-energy amorphous systems during extrusion
would enhance the drug release from the extrudates. However, the impact of utilized surfactants
in the formulation on the release of curcumin was not clearly understood. Therefore, drug release
profiles obtained from all of the melt extrudates and the pure drug were compared. The
interaction of curcumin with various charged aqueous surfactant solutions showed it exists in
deprotonated enol form in surfactant solutions. The nitro and hydroxyl groups of o-nitrophenol
interact with the carbonyl and hydroxyl groups of the enol form of curcumin by forming ground
state complex through hydrogen bonds and offered interesting information about the nature of
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the interactions between the aqueous surfactant solutions and curcumin depending on charge of
head group of the surfactant.
All of the extrudates released significantly higher amounts of curcumin (~64-100%)
compared to that of the pure drug (~20%). Moreover, effect of charged surfactants and their
concentrations on the release of curcumin was predominant. Increase in the SLS concentration
from 2.5% to 10% decreased the drug release from 95.4% to 54.5% after 60 minutes (Figure 43A). This decrease in drug release could be attributed to the hydrolytic degradation of Curcumin
in the alkaline pH (8.5-9.0) of dissolution medium (67). It has been reported that the Curcumin
undergoes deprotonation in alkaline pH and exists as a negatively charged molecule (Cur3-). The
SLS micelles cannot prevent the degradation of the compound due to the electrostatic repulsions
between the negatively charged head groups and Cur3-, resulting in the dissociation of Cur3- from
the micelle followed by its alkaline hydrolysis in the aqueous phase of the solution (68).
On the contrary, increased drug release was noticed with increasing concentration of
CTAB from 2.5% to 10% (Figure 4-3B). This could be attributed to the improved stability of
Curcumin due to its interaction with CTAB molecules. The cationic surfactants stabilize
deprotonated Curcumin, Cur3-, due to the attractive electrostatic interactions between the ionized
drug and the positively charged CTAB head groups. No significant improvement in the drug
dissolution was observed with increasing concentrations of non-ionic surfactant, Pluronic F127,
when compared to the control formulation containing no surfactant, but only curcumin and
soluplus® (Figure 4-3C).
All of these formulations were stored in accelerated conditions (40°C/75% RH) to study
their physical stability. These stored formulations were subjected to DSC analysis at the end of
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three months period and none of them exhibited recrystallization of curcumin in the extrudates
(data not presented), demonstrating the physical stability of the formulations.
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Figure 4-3: Effect of Surfactant Concentrations on Curcumin Dissolution from Hot-Melt
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Extrudates – (A) SLS; (B) CTAB; (C) Pluronic F127
4.4. Conclusions
Curcumin was found to be miscible in soluplus® up to 50% drug load. Both, charge and
the concentration of surfactant had a significant impact on the drug release from the HME
extrudates. HME has been successfully utilized in conjunction with Soluplus®, and other
functional excipients to improve the physical stability and the drug release. Soluplus® may
provide a solution to increase solubility of poorly soluble drugs.
4.5. Acknowledgements
This study was supported by HRSA/OFAM/DGMO grant#D1DHP20294 and
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CHAPTER - 5
Summary and Conclusions
5.1.

Hot Melt Extrusion: A Promising Technique to Produce a Novel Abuse-Deterrent
Formulation
HME was demonstrated as a viable technique with a potential to develop novel abusedeterrent formulations
PEO 301 demonstrated its utility as a feasible TR matrix
HPMC K15M in combination with CBP significantly improved the gelling characteristics
in water and alcohol
The optimized response models created for ‘%API extracted in water’ and ‘% API
extracted in alcohol’ also correlated well with the data generated, validating the
developed model.

5.2. Characterization of Kollidon® VA 64 Hot Melt Extrudates: Influence of Formulation
and Process Parameters on Dissolution and Stability Characteristics
Kollidon VA® 64 was extrudable at 75% w/w with only a model drug in the formulation.
Both of the processing parameters, temperature and screw speed, had a significant impact
on the post-processing drug content of the final extrudates.
NIF forms a stable amorphous solid dispersion in Kollidon VA® 64 matrix.
Drug release from all of the hot melt extrudates produced was similar. Moreover, release
from the extrudates was found to be superior compared to the physical mixtures.
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NIF was found to be physically and chemically stable throughout the study period.
5.3. Characterization of Soluplus® Hot Melt Extrudates: Effect of Formulation and Process
Parameters on Miscibility, Dissolution and Stability Characteristics
At 10% and 20% drug load, there is complete solubilization of CTZ in Soluplus ®.
However, at higher drug loading of CTZ (30% drug load), the increase in residence time
of the formulation in the extrusion barrel helps aid solubilization of CTZ.
Drug load and heat exposure/residence time had a significant impact on the drug-polymer
miscibility in the final extrudates, which was confirmed by DSC and FTIR Studies.
Both, the drug load and residence time had a significant impact on the CTZ release from
the melt extrudates.
CTZ forms an amorphous solid dispersion within the Soluplus® matrix, and the melt
extrudates containing up to 30% drug load were found to be physically and chemically
stable for a period of 3 months.
Moreover, Soluplus® was extrudable at 90% w/w with only a model drug in the
formulation.
Soluplus® combines the benefits of solid solutions and solubilization which thereby
increases solubility of poorly soluble drugs.
5.4. Influence of Hot Melt Extrusion Technology, and Effect of Type and Concentration of
Surfactants on Miscibility and Drug Release from Soluplus®-Curcumin Mixtures
HME has been successfully utilized in conjunction with Soluplus®, and other functional
excipients to improve the physical stability and the drug release
Curcumin formed a single phase miscible system in soluplus® up to 50% drug load.
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Both, charge and the concentration of surfactant had a significant impact on the drug
release from the HME extrudates.
Extrudates were found to be physically stable throughout the storage period of three
months under accelerated storage conditions.
Soluplus®, in combination with appropriate surfactants may provide a solution to increase
solubility and stability of the poorly soluble drugs.
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